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ABBREVIATIONS 
ARI  Adjusted Rand Index 
AUC  Area Under Curve 
AVI  Adjusted Variation of Information 
BIC  Bayesian Information Criterion 
BMBF  German Federal Ministry for Education and Research 
CDT   Cold Detection Threshold 
CI  Confidence Interval 
CPT   Cold Pain Threshold 
CRPS  Complex Regional Pain Syndrome 
DB  Database 
DET  Deterministic algorithm 
DFNS  German Research Network on Neuropathic Pain 
DMA   Dynamic Mechanical Allodynia 
dPNP  diabetic Polyneuropathy 
EM  Expectation Maximization 
EMA  European Medicines Agency 
H  Healthy sensory profile 
HFS  electrical High-Frequency Stimulation  
HIV  Human Immunodeficit Virus 
HPT   Heat Pain Threshold 
i.d.  intradermal 
IASP  International Association for the Study of Pain 
IENFD  Intra-Epidermal Nerve Fiber Density 
IMI  Innovative Medicines Initiative 
IN  Irritable Nociceptor 
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MDT   Mechanical Detection Threshold 
MH  Mechanical Hyperalgesia phenotype 
MPS   Mechanical Pain Sensitivity 
MPT   Mechanical Pain Threshold 
NB  Nerve Block mechanistic phenotype 
NNT  Number Needed to Treat 
NPSI   Neuropathic Pain Symptom Inventory 
PH  Primary Hyperalgesia mechanistic phenotype 
PHN  Post-Herpetic Neuralgia 
PHS   Paradoxical Heat Sensation 
PiNS  Pain in Neuropathy Study 
PNI  Peripheral Nerve Injury 
PNP   Polyneuropathy 
PPT   Pressure Pain Threshold 
QST   Quantitative Sensory Testing 
RAD  Radiculopathy 
ROC  Receiver Operating Characteristics 
SH  Secondary Hyperalgesia mechanistic phenotype 
SL  Sensory Loss phenotype 
TH  Thermal Hyperalgesia phenotype 
TN  Trigeminal Neuralgia 
TRPV1 Transient Receptor Potential Vanilloid 1 
TSL   Thermal Sensory Limen 
UVB  Ultraviolet Radiation B 
VDT   Vibration Detection Threshold 
WDT   Warm Detection Threshold 
WUR   Wind-Up Ratio 
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1 INTRODUCTION 
1.1 Pain and neuropathic pain 
Pain is defined as an “unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage” by the 
International Association for the Study of Pain (IASP) (Marskey et al., 1979). While 
acute pain serves as a warning and protective system activated by tissue damage or 
trauma, chronic and persistent pain may turn into a pathological state of its own 
(Loeser and Treede, 2008). If the pathophysiological basis is known, chronic pain 
can be subdivided into two major groups: 
- Nociceptive pain is arising from activation of nociceptors (sensory neurons 
reporting actual or potential tissue damage). Chronic inflammation can lead to 
inflammatory pain, a chronic form of nociceptive pain. The nociceptive system 
itself is not directly affected, but may alter over time via sensitization (Loeser 
and Treede, 2008). 
- Neuropathic pain results from an injury or disease to the nociceptive system 
(Treede et al., 2008; Finnerup et al., 2016) and can be caused peripherally 
(peripheral neuropathic pain) or in the central nervous system (central 
neuropathic pain). 
Historically, peripheral neuropathic pain is classified based on the underlying disease 
or event initiating the nervous damage, such as diabetes, HIV, or chemotherapy-
induced polyneuropathy (PNP), post-traumatic peripheral nerve injury (PNI), 
radiculopathy (RAD), trigeminal neuralgia (TN) or post-herpetic neuralgia (PHN) 
(Colloca et al., 2017). Treatment guidelines are often based on these etiologies, 
though it has become evident over the last decades that this approach is not 
sufficient, as first line treatment fails in over 50% of patients (Finnerup et al., 2015; 
Bouhassira and Attal, 2016). While written ten years ago, the following devastating 
statement remains largely valid: “The management of patients with chronic NP 
[neuropathic pain, A/N] is complex and response to existing treatments is often 
inadequate. Even with well-established NP medications, effectiveness is 
unpredictable, dosing can be complicated, analgesic onset is delayed, and side 
effects are common” (Dworkin et al., 2007). 
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The fact that common symptoms and signs of neuropathic pain appear across 
etiologies, while varying in pattern within etiologies, has led to the idea that distinct 
pathogenic mechanisms of neuropathic pain appear across etiologies (Fields et al., 
1998; Woolf and Mannion, 1999; Campbell and Meyer, 2006; Baron et al., 2012; von 
Hehn et al., 2012). Treatment of neuropathic pain therefore should be aiming at 
mechanisms rather than at etiology.  
1.2 Peripheral sensory signal transduction 
The somatosensory (nervous) system comprises the afferent peripheral sensory 
receptor neurons, and their subsequent second-order neurons in the central nervous 
system (Kandel et al., 2013). All afferent sensory receptor neurons are pseudo-
unipolar neurons based in the dorsal root (or trigeminal) ganglia with a single axon 
that divides at a T-junction into a peripheral axon, innervating skin or deep tissue, 
and a central axon, transmitting signals onto secondary neurons in the spinal cord or 
medulla oblongata (Squire et al., 2008). Sensory neurons differ, however, in degree 
of myelination, and (conclusively) signal conduction velocity (Kandel et al., 2013). 
Three major fiber types can be distinguished in primary afferent neurons:  
- Aβ-fibers – thickly myelinated (nerve fiber diameter 6 – 12 μm), high 
conduction velocity (36 – 72 m/s) (Kandel et al., 2013) – innervate cutaneous 
mechanoreceptors (e.g. vibration, pressure) (Squire et al., 2008), 
- Aδ-fibers – thinly myelinated (nerve fiber diameter 1 – 6 μm), medium 
conduction velocity (3 – 36 m/s) (Kandel et al., 2013) – detect cold and 
noxious stimuli (Squire et al., 2008) and 
- C-fibers – unmyelinated (nerve fiber diameter 0.2 – 1.5 μm), slow conduction 
velocity (0.4 – 2 m/s) (Kandel et al., 2013) – transmit warm and noxious stimuli 
(Squire et al., 2008). 
1.3 Nociception 
Noxious stimuli are transduced (e.g. via TRPV1) and subsequently transformed into 
action potential trains (e.g. via NaV 1.7, 1.8, etc.). These trains are conducted via 
small, thinly or unmyelinated Aδ- or C-fibers. The divergent conduction velocity of 
these fibers results in the concept of first and second pain: the former, conducted by 
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faster Aδ-fibers, is discriminative and rapidly induces efferent response, the latter, 
conducted by slower C-fibers, is less localized and of longer duration (Squire et al., 
2008).  
Nociceptors with Aδ-fibers are sensitive to either mechanical stimuli and induce pain 
of sharp or pricking quality, or are sensitive to mechanical and heat stimuli and 
induce pain of burning quality (Kandel et al., 2013). Nociceptors innervated by C-
fibers are polymodal or sensitive to mechanical and cold stimuli and induce pain of 
burning or freezing quality (Kandel et al., 2013). It should be noted that the majority 
of nociceptors are polymodal and respond to various stimuli, such as heat, cold, 
sharp or blunt pressure, or chemicals, but the sensitivity spectrum varies broadly 
between nociceptors (Kandel et al., 2013).  
1.4 Mechanisms of neuropathic pain 
According to a recent review (Colloca et al., 2017), along the nociceptive pathways, 
at three levels the generation of neuropathic pain can take place: 
1. First-order nociceptor ion channels (peripheral sensitization). 
Altered function of transduction channels (e.g. TRPV1 (Haanpaa and Treede, 
2012)), as well as in- or decreased activity or expression of sodium, potassium 
and/or calcium channels in affected afferent nerves can induce spontaneous 
pain or hyperexcitability of the affected nerves, which has been shown for 
example in case of congenital overexpression of sodium channels, which can 
induce painful diseases like erythromelalgia (McDonnell et al., 2016). Similarly, 
increased sodium or decreased potassium channel function can induce 
hyperexcitable nociceptors (often called IN = irritable nociceptors) (Fields et 
al., 1998; Tesfaye et al., 2013). These can also cause spontaneous pain via 
ectopic activity. Increased pain sensitivity due to peripheral sensitization is 
limited to the site of injury, trauma or disease and called primary hyperalgesia 
(Treede et al., 1992; Hucho and Levine, 2007). 
2. Second-order neurons (central sensitization). 
Enhanced excitability of second order nociceptive neurons can increase their 
response to nociceptor input and widen their receptive field so that input from 
non-nociceptive sensory neurons induces nociceptive transduction (Woolf, 
2011). Central sensitization can be induced by primary hyperalgesia and 
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accounts for secondary hyperalgesia (pain increased in spatial extend beyond 
the initial area of the injury or disease) and allodynia (painful sensation to non-
painful stimuli) (Baron et al., 2013). 
3. Inhibitory modulation. 
Descending modulatory pathways and inhibitory interneurons can be impaired 
in patients with neuropathic pain, shifting the balance between pain inhibition 
and excitation further towards excitation (Colloca et al., 2017). It has been 
shown that the extent of conditioned pain modulation, where the perceived 
pain intensity of a steady painful test stimulus is reduced by applying a second 
tonic painful stimulus, is reduced in many patients with chronic pain (Lewis et 
al., 2012). 
These mechanisms are, as stated above, present across etiologies of neuropathic 
pain (though varying in frequency), they may co-exist and enhance or facilitate each 
other, and, most importantly, are assumed to respond to distinct forms of treatment 
(Finnerup et al., 2015). Therefore, a mechanistic classification of neuropathic pain 
has been under debate for over 25 years now (Fields et al., 1998; Woolf et al., 1998; 
Baumgartner et al., 2002; Baron et al., 2012; von Hehn et al., 2012; Edwards et al., 
2016). 
1.5 Sensory phenotyping 
To establish a mechanism-based classification, it is crucial to be able to detect and 
describe the mechanisms involved in the generation of pain in the individual patient. 
A first step can be patient-recorded questionnaires, capturing subjective reports of 
dimensions of neuropathic pain like the Neuropathic Pain Symptom Inventory (NPSI) 
(Bouhassira et al., 2004). As a second step, bedside testing of sensory signs like loss 
of thermal or mechanical detection or painful reaction to stimuli that are normally not 
perceived as painful may indicate involvement of mechanisms. However, both 
methods are subjective and hardly comparable between patients. 
A comprehensive way to capture a patient’s sensory function is Quantitative Sensory 
Testing (QST) (Krumova et al., 2012a). When performed in accordance with the 
DFNS (German Research Network on Neuropathic Pain) protocol (Rolke et al., 
2006b), QST assess thermal and mechanical detection and pain thresholds, 
capturing various aspects of neuropathic pain:  
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1. Denervation/deafferentation – increased detection thresholds indicate loss of 
activity and/or presence of Aβ- (mechanical detection), Aδ- (cold detection) or 
C-fiber sensory neurons. 
2. Peripheral sensitization – heat hyperalgesia or increased deep pain sensitivity 
to blunt pressure in combination with unimpaired thermal detection may 
indicate irritable nociceptors. 
3. Central sensitization – dynamic mechanical allodynia, increased pinprick pain 
sensitivity and cold hyperalgesia indicate central sensitization. 
4. Modulatory descending pathways – an increased wind-up ratio (rating of a 
single painful stimulus compared to a series of ten such stimuli) indicates 
impaired descending noxious inhibition controls. 
While QST has shown its capacity to identify and separate groups of patients with 
neuropathic pain (Maier et al., 2010; Smith et al., 2017), its usefulness for individual 
treatment is under discussion (Hansson et al., 2007; Backonja et al., 2013). Detection 
and pain thresholds vary broadly within healthy populations, and are influenced by 
age, gender, tested body region, and more problematic, by many factors that are 
impossible to control for, like genetics, epigenetics and individual development. Still, 
this is a frequent phenomenon in medicine and even more problematic in other tests 
assessing the nervous system (e.g. counting intraepidermal nerve fibers after skin 
biopsy (Isak et al., 2017)). 
1.6 Aims and objectives 
The European consortia IMI (Innovative Medicines Initiative) Europain, Neuropain 
and the DFNS have gathered QST data of 945 patients with peripheral neuropathic 
pain and 657 healthy participants with transient sensory changes due to surrogate 
models for neuropathic pain. In addition, reference data of healthy participants was 
collected in the DFNS (Rolke et al., 2006a; Blankenburg et al., 2010; Magerl et al., 
2010; Pfau et al., 2014; Vollert et al., 2016a), and 188 healthy participants from 
additional German and European centers were included subsequently (Vollert et al., 
2016a). All data have been collected in a central database in Bochum, Germany 
(Maier et al., 2010; Vollert et al., 2016a; Baron et al., 2017; Vollert et al., 2017b). 
While examination of patients and healthy participants was performed by physicians 
at the respective sites and collection and organization of data in a unified database 
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with high data quality was the central task of my master thesis (Vollert et al., 2015; 
Vollert et al., 2016b), scope of the present thesis was to adapt, develop and perform 
all mathematical analysis necessary to develop an individual algorithm to assign 
patients to sensory phenotypes that are linked to mechanisms of pain generation. En 
detail, aim of this work was to use this data to: 
1. Perform a systematic analysis of heterogeneity of QST assessment of patients 
and healthy participants between the participating European centers, to show 
that comparability between centers is guaranteed, a central prerequisite for 
analyzing the data as a homogenous dataset. 
2. Use unsupervised clustering methods to identify subgroups of sensory profiles 
appearing across etiologies of peripheral neuropathic pain and may indicate 
underlying mechanisms of pathophysiology. 
3. Develop an algorithm that enables assignment of individual patients to one or 
more of the subgroups identified in (2) based on the patient’s QST profile. 
4. Apply the algorithm from (3) to 83 patients with peripheral neuropathic pain, 
whose pain relief after treatment with oxcarbazepine  is known from a former 
study (Demant et al., 2014). Oxcarbazepine blocks sodium channels that are 
mainly located on small nerve fibers, and is therefore thought to be ineffective 
in patients with pain linked to deafferentation. In their study, Demant et al. 
found that patients with intact thermal detection show a significantly increased 
pain relief after treatment with oxcarbazepine compared to patients with loss of 
thermal detection. A pain relief that is significantly higher in a sensory 
subgroup from (2) with intact thermal detection compared to those with loss of 
thermal detection would indicate mechanistic variance in pain generation 
between subgroups. 
5. Apply the algorithm from (3) to 335 patients with painful peripheral nerve 
injury, 151 patients with painful diabetic neuropathy, and 97 patients with post-
herpetic neuralgia. Based on the frequency of each phenotype in each 
etiology, sample sizes of study populations that need to be screened to reach 
a sub-population large enough to conduct a phenotype-stratified study were to 
be calculated. 
6. To create a database of human surrogate models studied with full QST 
profiles and to perform a similar cluster analysis and a similar individual 
algorithm as in (3) in 657 healthy participants with transient sensory changes 
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due to surrogate models for denervation, peripheral sensitization and central 
sensitization. These represent well-studied mechanisms.  
7. To further validate the phenotypes identified in (2) by submitting them to the 
mechanism-based individual algorithm developed in (6). An emergence of 
similar phenotypes in surrogate models that are similar in mechanism would 
further strengthen the concept of sensory phenotypes representing 
mechanisms of neuropathic pain. 
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2 METHODS 
2.1 Consortia and participating centers 
The DFNS (http://www.neuropathischer-schmerz.de) was formed in 2002 and 
financed by a BMBF (federal ministry for education and research) grant to investigate 
mechanisms and treatments of neuropathic pain. Forming universities were the Ruhr 
University, Bochum, University of Schleswig Holstein, Kiel, Technical University, 
Munich, Ruprecht-Karls-University, Heidelberg, Johannes-Gutenberg-University, 
Mainz, University of Erlangen, University of Tübingen, University of Würzburg, 
University of Ulm. The study protocol was approved by the ethics committee of the 
University Hospital Kiel and subsequently by the ethics committees of all participating 
centers. Subsequently, the University Hospital of the Goethe-University, Frankfurt am 
Main, joined the DFNS and participated in collecting data from human surrogate 
models of neuropathic pain. 
The EUROPAIN project (http://www.imieuropain.org) was founded in 2009 and 
financed by the European union’s seventh framework programme. Data for this study 
were collected by the following centers: Aarhus University, Denmark, Ruhr-
University, Bochum, Germany, University of Schleswig Holstein, Kiel, Germany, 
Technical University, Munich, Germany, Medical Faculty Mannheim, Ruprecht-Karls-
University, Heidelberg, Germany. The ethics committee of each center approved the 
study protocol individually. 
The NEUROPAIN project is an investigator-initiated project sponsored by Pfizer. 
Data for this study were collected by the following centers: Aarhus University, 
Denmark, Ruhr-University Bochum, Germany, University of Schleswig Holstein, Kiel, 
Germany, Technical University, Munich, Germany, Medical Faculty Mannheim, 
Ruprecht-Karls-University, Heidelberg, Germany, Université Versailles-Saint-Quentin, 
Versailles, France, Sapienza University, Rome, Italy, Helsinki University Central 
Hospital, Finland, Karolinska Institutet, Stockholm, Sweden, Benedictus Hospital 
Tutzing, Germany, Imperial College, London, United Kingdom, Neuroscience 
Technologies, Ltd., Barcelona, Spain. The ethics committee for each center approved 
the study protocol individually. 
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The Pain in Neuropathy Study (PiNS) was supported by the Wellcome Trust, and the 
European Union's Horizon 2020 research and innovation program. Data for this study 
were collected at the Oxford University, Oxford, United Kingdom, Imperial College, 
London, United Kingdom, and Sheffield Teaching Hospitals, Sheffield, United 
Kingdom. The ethics committee for each center approved the study protocol 
individually. 
All participating centers underwent strict quality control (Geber et al., 2009; Magerl et 
al., 2010; Vollert et al., 2015) to ensure comparability of QST assessments between 
centers. 
2.2 Patient and participant selection 
2.2.1 Patients 
[The following section has been taken in parts and modified from (Vollert et al., 
2016b) and (Baron et al., 2017).] 
Inclusion criteria for patients were carefully checked by a physician experienced in 
pain medicine at the local center. For each diagnosis, inclusion criteria were as 
follows:  
- Polyneuropathy: pathological electroneurography or pathologically decreased 
vibration detection thresholds at two of four sites (< 5/8) at the lower limb, 
which could not be explained by another disease, or pain with polyneuropathy-
type location and evidence of small fiber neuropathy based on skin punch 
biopsy, laser-evoked potentials or bedside thermal testing, which could not be 
explained by another disease. 
- Peripheral nerve injury: history of traumatic nerve injury of the distal upper or 
lower limb and sensory-motor abnormalities confined to the innervation 
territory of the injured nervous structure or idiopathic sensory trigeminal 
neuropathy or iatrogenic mandibular neuropathy (i.e., inferior alveolar or 
lingual nerve neuropathy after various kinds of intraoral procedures) or 
trigeminal neuropathy secondary to compression, trigeminal neuropathy 
secondary to percutaneous lesions of the ganglion and sensory loss in the 
neuroanatomical adequate trigeminal territory. 
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- Post-herpetic neuralgia: unilateral zoster rash in the facial or thoracic area with 
post-zoster scarring, hypo- or hyperpigmentation in the affected dermatome or 
sensory deficit around the previous zoster rash determined by bedside-testing. 
- radicular lesion: pain in the L5 and/or S1 dermatome and positive straight leg 
raising test or sensory deficit within the matching dermatome or diminished 
Achilles tendon reflex for S1 lesions and MRI of the lumbar spine confirming 
nerve root impairment by a herniated intervertebral disk or electromyography 
showing denervation in the L5 or S1 territory. 
Exclusion criteria were age under 18 years, missing informed consent, insufficient 
language skills or other communication problems, pain treatment by topical local 
anesthetics for ≥ 7 days in the last 4 months or by topical capsaicin in the last 6 
months, comorbidities treated by anticonvulsants or antidepressants, other pain 
locations with pain intensities ≥ 6 on ≥ 15 days/ month, other severe systemic or focal 
diseases of the central nervous system (e.g., stroke, spinal cord lesion), spinal canal 
stenosis, peripheral vascular disease (Fontaine stage II or higher), pending litigation 
and major cognitive or psychiatric disorders. In the cases of unilateral pain 
syndromes, contralateral neuropathies or painful conditions of the contralateral limb 
had to be excluded. Datasets were excluded in the case of incomplete records (e.g., 
no precise diagnosis available, more than 2 missing variables of the QST in the 
affected area, no information about age, gender or other demographic data). 
2.2.2 Healthy participants 
Healthy participants were included based on the recommendations by Gierthmühlen 
et al. (Gierthmuhlen et al., 2015) and collected by ten centers from the DFNS, IMI 
Europain and Neuropain for quality assurance purposes (Vollert et al., 2015) during 
the certification process of these centers (Geber et al., 2009).   
2.2.3 Human surrogate models of neuropathic pain 
The following human surrogate models for neuropathic pain were conducted within 
the DFNS and included in the analysis (Klein et al., 2005; Vollert et al., 2017b): 
- A-fiber-block (unpublished data collected in Kiel and Mannheim, methods as in 
(Ziegler et al., 1999)). Selectively blocking A-fibers leads to strongly decreased 
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sensory function (except warm detection, which is C-fiber mediated) and is a 
model for selective deafferentation/denervation of myelinated nerves (e.g. 
demyelinating polyneuropathy).  
- Topical lidocaine cream application. Topical lidocaine induces loss of sensory 
function and therefore is a model of denervation/deafferentation (Krumova et 
al., 2012b). 
- Topical capsaicin application, using cream, watery solution, or patch. The 
application of topical capsaicin induces peripheral sensitization, and can lead 
over time to a secondary hyperalgesia beyond the immediately affected area, 
a model for peripheral sensitization leading to central sensitization (Baron et 
al., 2013; Lotsch et al., 2015) 
- UV-B light irradiation (unpublished data collected in Mannheim and published 
data, methods as in (Gustorff et al., 2013)). The sunburn model induces 
primary and secondary hyperalgesia similar to topical capsaicin (Gustorff et 
al., 2013) 
- Intradermal capsaicin injection (unpublished data collected in Kiel, Mannheim 
and TU Munich, methods as in  (Magerl and Treede, 2004). The injection 
leads to secondary hyperalgesia, without inducing primary hyperalgesia first 
(Magerl and Treede, 2004). 
- Cutaneous electrical high-frequency stimulation (HFS). Cutaneous HFS leads 
to mechanical hyperalgesia and allodynia, and therefore is a model of central 
sensitization (Lang et al., 2007). 
- Muscular electrical high-frequency stimulation. HFS in the muscle is thought to 
lead to peripheral sensitization (Schilder et al., 2016). 
- Topical menthol application. As topical menthol application leads to primary 
and secondary cold and mechanical hyperalgesia, it is a model for central 
sensitization (Wasner et al., 2004; Binder et al., 2011). 
- Topical application of capsaicin solution in combination with lidocaine patch. 
This model induces primary hyperalgesia (peripheral sensitization) in 
combination with loss of function, e.g. numbness (Enax-Krumova et al., 2017). 
2.3 QST protocol 
QST in accordance with the DFNS protocol assesses 13 parameters: cold and warm 
detection thresholds (CDT and WDT, respectively), the thermal sensory limen during 
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alternating cold and warm stimuli and the number of paradoxical heat sensations 
(PHS) during this procedure, cold and heat pain thresholds (CPT and HPT, 
respectively), tactile (mechanical) detection threshold (MDT), mechanical pain 
threshold and sensitivity to pinprick stimuli (MPT, MPS), dynamical mechanical 
allodynia to touch with a brush, cotton wool or Q-tip (DMA), the wind-up ratio (WUR) 
of the perceived pain of a single pinprick stimuli compared to a series of ten stimuli, 
vibration detection threshold (VDT) and deep pain sensitivity to blunt pain (pressure 
pain threshold, PPT) (Rolke et al., 2006a).  
Thermal sensory and pain thresholds were performed using either a TSA 2001-II 
(MEDOC, Israel) or a MSA (SOMEDIC, Sweden) that in- or decreased temperature 
by 1°C per second (Rolke et al., 2006b). For the TSL, six warm and cool stimuli were 
applied. The participant was asked whether he or she felt a cold or a warm stimulus, 
and the number of PHS (warm sensations during cold stimuli) was recorded. MDT 
was defined as the geometric mean of 5 series of stimuli ascending and descending 
between 0.25 and 512mN by a standardized set of von Frey hairs, mechanical pain 
threshold as the geometric mean of 5 series of stimuli ascending and descending by 
applying pinprick stimuli between 8 and 512mN (Rolke et al., 2006b). MPS and DMA 
were assessed by applying a total of 50 stimuli (35 pinprick and 15 light tactile in a 
balanced protocol) and asking patients to give a pain rating on a 0 (no pain) to 100 
(worst pain imaginable) NRS scale. MPS was calculated as the geometric mean of 
the pain ratings of the pinprick stimuli, DMA as the geometric mean of the pain rating 
of the tactile stimuli. For the WUR the perceived intensity of a single pinprick stimulus 
was compared with that of a series of 10 repetitive pinprick stimuli of the same 
physical intensity on a 0-100 NRS scale, as an average of five series (Rolke et al., 
2006b). VDT was assessed with a Rydel–Seiffer graded tuning fork (64 Hz, 8/8 scale, 
mean of three testing series) and PPT was determined over muscle with a pressure 
gauge device (FDN200, Wagner Instruments, USA), exerting forces up to 2000 kPa, 
as a mean of three series of ascending stimulus intensities, each slowly increasing 
(50 kPa/s) (Rolke et al., 2006b). 
2.4 z-transformation 
The initial assessment of 180 healthy participants for the DFNS reference database 
revealed that all parameters except PHS and DMA could be transformed (partly in 
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log-space) to a standard normal distribution (Rolke et al., 2006a; Magerl et al., 2010; 
Pfau et al., 2014). This process, called z-transformation, normalizes all values to a 
mean = 0 and a standard deviation = 1. Subsequently, all QST results of patients and 
healthy participants were transformed in accordance to this normalization. The z-
transformation normalizes for age decade, gender and tested body region, thus 
making pain and detection thresholds comparable between patients with different 
age and gender, with nerves affected e.g. at the face or the feet. Abnormal values 
are defined as values beyond the 95% confidence interval. While individual z-scores 
are considered as abnormal if beyond ± 1.96 (Rolke et al., 2006a), for groups of 
patients, z-scores of ± 1.0 have been shown to be of clinical significance, as they 
include a relevant number of patients with abnormal values (Maier et al., 2010). 
DMA and PHS, which do not normally occur in healthy participants, cannot be z-
transformed. They are usually presented as percentages of presence, but for use in 
statistical analysis, they can be transformed to pseudo-z-values: DMA can be coded 
into a 0/2/3-variable representing no DMA (coded as 0), DMA with average pain 
ratings below 1 on a 0-100 NRS scale (coded as +2) and DMA with average pain 
ratings between 1 and 100 (coded as +3). PHS can be transformed to a binary 0/2-
variable showing absence (coded as 0) or presence (coded as +2) of pathological 
values (Baron et al., 2017).  
As many surrogate models were applied at the volar lower arm or upper thigh, which 
are not standardized areas, data of the subjects tested in the same area before 
treatment, or, if this data was unavailable, of the contralateral untreated side was 
compared used to calculate effect sizes (Cohen’s d (Cohen, 2013)). This measure 
normalizes changes in the mean value before and after treatment to standard 
deviation, i.e. an effect size = 1 equals a change in the mean value after treatment 
that is equal to the standard deviation of the sample. There are no general 
interpretations of “good” effect sizes, but it is often considered that effect sizes below 
0.3 can be considered small, and above 0.7 can be considered as large treatment 
effects (Cohen, 1992). 
2.5 Analysis of heterogeneity 
[The following section has been taken in parts and modified from (Vollert et al., 
2016a).] 
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To assess the variability of QST results across the different centers, random effects 
models for the eleven normally distributed QST parameters were adopted, with the 
QST z-value of a certain parameter as the dependent variable and center as the 
random effect. For the analysis of cold detection thresholds in patients suffering from 
polyneuropathy, let 𝑌𝑖𝑗 be the CDT z-value of 𝑗th patient (1 ≤ 𝑗 ≤ 𝑁) in the 𝑖th center 
(1 ≤ 𝑖 ≤ 𝑀), the model is specified as: 
𝐹(1):   𝑌𝑖𝑗 =  𝜇 + 𝛼𝑖 + 𝜀𝑖𝑗 
𝐹(2𝑎):   𝜀𝑖𝑗 ~ 𝑁(0, 𝜎
2) 
𝐹(2𝑏):   𝛼𝑖  ~ 𝑁(0, 𝜎𝜇
2) 
where 𝜇 is the overall mean CDT z-value across all centers, 𝑎𝑖  is the unobserved 
center-specific random effect and ɛ𝑖𝑗  is the individual unexplained effect. The model 
is fitted so that 𝜀𝑖𝑗 and 𝑎𝑖 are normally distributed with a mean value = 0 (F(2a) and 
F(2b)). The estimated center-specific mean z-values (𝜇 + 𝑎𝑖 for 1 ≤ 𝑖 ≤ 𝑀) and the 
corresponding 95% confidence intervals from Model (1) are graphically displayed in 
forest plots separately for PNP, PNI and healthy participants, with the Y-axis showing 
a running number for the centers for all 11 QST parameters and the X-axis 
presenting the center-specific mean z-value. The I² statistic (Higgins and Thompson, 
2002) was employed to quantify the heterogeneity of mean z-values across the 
centers. This statistic ranges from 0 to 100% and it measures the percentage of 
variation across studies that is due to true heterogeneity rather than chance. The 
confidence interval estimates of I² were computed based on the test-based method of 
Higgins and Thompson (Higgins and Thompson, 2002).  
2.6 Cluster analysis protocol 
[The following section has been taken in parts and modified from (Baron et al., 
2017).] 
A cluster analysis was performed to unravel distinguishable subgroups of QST-
profiles. The procedure of this analysis was identical for patients suffering from 
peripheral neuropathic pain (Baron et al., 2017) and healthy participants under 
conditions that induce human surrogate models of neuropathic pain, in order to 
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guarantee comparability between the results. We made no a-priori-assumptions 
about the expected number of clusters and applied a k-means-approach for a 
number of k clusters ranging from 2 to 10 (MacQueen, 1967). A two-step protocol 
was used to determine the optimum number of clusters: 
- Negative silhouettes as exclusion criterion. A silhouette width is a value that 
can be calculated for each subject in each cluster and ranges between -1 and 
+1 (Rousseeuw, 1987). Positive values near +1 indicate a subject that can 
unambiguously be allocated to a certain cluster, values near zero indicate 
subjects that are on the edge between clusters, and negative values indicate 
that these subjects are allocated to a cluster that is not their nearest cluster. 
This is possible because if they would be allocated to their nearest cluster, the 
cluster mean would shift so that other subjects are then in a cluster that is not 
their nearest. A mean silhouette width well above zero for a cluster indicates 
that said cluster is clearly separated from the others, while a mean silhouette 
width below zero indicates a cluster that is rather a statistical artifact than a 
real subgroup. Therefore, a high count of negative silhouettes or a cluster with 
a mean silhouette width below zero indicate a cluster solution that is highly 
fragmented. Thus, to control for statistical artefacts, we excluded all solutions 
with at least one cluster with a negative mean silhouette width, and all 
solutions with over 10% negative silhouette widths.  
- Comparability between clustering methods. The remaining solutions were 
compared to two additional cluster methods with significantly different 
mathematical background, validating that the final solution is not dependent on 
the clustering method. We decided on a robust hierarchical clustering method 
(maximum linkage) and an Expectation Maximization (EM) algorithm 
(Dempster et al., 1977). Both solutions were compared to the initial k-means 
clustering, using the adjusted rand index (ARI) and the adjusted variation of 
information (AVI). While the ARI measures similarity on a scale from 0 – 1 
(high values are preferable), the AVI measures dissimilarity on the same scale 
(low values are preferable) (Rand, 1971). Final criterion for the decision 
between otherwise equal cluster solutions was the Bayesian Information 
Criterion (BIC) which captures the gain of information by increased number of 
clusters. As a rule of thumb, the higher number of clusters is preferable, if the 
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difference between the BICs of both solutions (Delta-BIC) is larger than ten 
(Schwarz, 1978). 
2.6.1 Validation sets 
To investigate the stability of the findings, for both cluster analyses (patients and 
surrogate models) a validation set was formed, in which additional k-means cluster 
analyses were performed, with a fixed number of clusters (as defined above).  
For patients suffering from peripheral neuropathic pain, this validation set was formed 
from patients with PNP, PNI and PHN who were collected either within the DFNS 
after closure of the initial database (Maier et al., 2010) or within the Europain 
consortium for treatment studies with oxcarbazepine and lidocaine (Demant et al., 
2014; Demant et al., 2015).  
For human surrogate models of neuropathic pain, no similar cohort was available. 
Therefore, 50% of all data (chosen by random number assignment) were excluded 
from the initial analysis to form the validation set. 
2.7 Individual sorting algorithm 
[The following section has been taken in parts and modified from (Vollert et al., 
2017a).] 
As QST z-values are (per definition) normally distributed, our approach was based on 
normally distributed probabilities. For each QST z-value of each parameter i and 
patient n, a probability can be calculated for a phenotype to be present based on the 
density function of said phenotype:  
 
𝐹(3):     𝑝𝑖𝑛,𝑚 = 
1
√2𝜋𝜎𝑖𝑚
2
 exp 
(
 
 
− 
(
  
(𝑥𝑖𝑛−𝜇𝑖𝑚)²
√2𝜎𝑖𝑚
2
 
)
 
)
 
 
 
 
With i = one of 13 QST parameters, n = the nth patient in a set of patients, m = one of 
the phenotypes determined in the cluster analysis of patients described above and 
conclusively, 𝜎𝑖𝑚 being the standard deviation of the ith QST parameter for the mth 
phenotype in the defining dataset (Baron et al., 2017), 𝜇𝑖𝑚 being the mean z-value of 
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the same QST parameter and phenotype in the defining dataset (Baron et al., 2017), 
and finally 𝑥𝑖𝑛 being the z-value found in the nth patient for the ith QST parameter. 
While this function will always reach its maximum at  𝑥𝑖𝑛 = 𝜇𝑖𝑚 , in relation to 
broadness of the standard deviation, density functions can become broader or 
narrower. This affects the maximum value the density function can reach. To control 
for these more or less broad functions, we normalized the formula so that a value that 
is equal to the mean of the phenotype equals 100%, leading to 
 
𝐹(4):     𝑝𝑖𝑛,𝑚
∗  = 1
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which can be simplified to 
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The resulting probability value is ranging from 0% to 100% and can be calculated for 
all i = 13 QST parameters and m phenotypes. By averaging the probability over the 
13 QST parameters, we quantify the similarity of the individual patient’s QST profile 
to the mean profile of each of the phenotypes.  
As a simple way of categorizing patients into phenotypes, we suggest sorting each 
patient to the phenotype with the highest probability value: 
1. Calculate F(5) for each of the 13 QST parameters. Use μ and σ for phenotype 
1.  
2. Average the 13 probabilities. The resulting value is the probability for this 
patient to show this phenotype. 
3. Repeat steps 1 and 2, using μ and σ for the next phenotype. Repeat for all 
phenotypes. 
4. Allocate the patient to the phenotype with the highest probability value. 
The algorithm as described above was applied to the patients from the original cohort 
(Baron et al., 2017) to demonstrate its general sorting capacity.  
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2.7.1 Simplified phenotyping 
As the DFNS protocol is comprehensive, it might be too complex to be applied in all 
clinical settings and in large clinical trials. If the cluster analysis showed that few 
parameters explain large parts of the variance between the discovered phenotypes, 
the accuracy of a phenotyping based on these in comparison to a phenotyping using 
the full protocol is analyzed.  
2.7.2 Discrimination analysis against healthy participants 
To show if and how the algorithm can discriminate patients with neuropathic pain 
from healthy participants, we introduced a fourth probability - not for a phenotype, but 
for being healthy. For this purpose, we applied the definition of QST z-values, to 
which a group of healthy participants ideally has a z-value mean = 0 (μ) with a 
standard deviation = 1 (σ) for each QST parameter. The original cluster patient 
cohort (Baron et al., 2017) (n = 902) and n = 188 healthy participants from the 
European cohort (Vollert et al., 2016a) underwent a modified version of the algorithm:  
1. Calculate F(5) for each of the 13 QST parameters. Use μ and σ for healthy.  
2. Average the 13 probabilities. The resulting value is the probability for this 
patient to show a healthy profile. 
3. Repeat steps 1 and 2, using μ and σ for all phenotypes. 
As this version of the algorithm does not sort each subject simply to the phenotype 
with the highest probability, this leaves every subject with a series of probabilities, 
one for each of the phenotypes of neuropathic pain, and one for being healthy. 
The probability of being healthy was used for a Receiver Operating Characteristics 
(ROC) plot (Zweig and Campbell, 1993). This graphical tool for assessing 
discriminatory power plots the false-positive rate (1 - speciﬁcity) on the x-axis versus 
the sensitivity of detecting patients on the y-axis for all possible probability values of 
being healthy. Each step in the ROC plot represents the specificity and sensitivity of 
one certain percentage. To assess the overall quality of separating healthy 
participants and patients via the probability for being healthy, the area under curve 
(AUC) and its 95% confidence interval were calculated (DeLong et al., 1988). To 
define a minimum probability, at which a subject should be considered being healthy, 
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the probability with the highest Youden-Index (sensitivity minus false-positive rate 
(Youden, 1950)) was chosen.  
2.7.3 Effectiveness for treatment with oxcarbazepine 
It has been shown in a recent study that the effectiveness of oxcarbazepine as 
treatment for neuropathic pain is dependent on the sensory phenotype of the patients 
(Demant et al., 2014). Oxcarbazepine is a blocker of voltage-gated sodium channels 
(McLean et al., 1994) and therefore has the potential to reduce neuropathic pain 
caused by overexpression or increased sensitivity of sodium channels (Ichikawa et 
al., 2001). This effect is, however, only possible in patients where this specific 
mechanism is present, and oxcarbazepine will therefore not help patients whose pain 
is generated more centrally (Katz et al., 2008). In their paper, Demant et al. 
phenotyped the patients as “irritable nociceptor” (IN, intact thermal detection, thermal 
or mechanical hyperalgesia) and “non-irritable nociceptor” (the remainder) (Demant 
et al., 2014). It was found that pain reduction was only significant in patients with 
“irritable nociceptor” phenotype. The number-needed-to-treat (number of patients that 
has to be treated with oxcarbazepine to find at least one patient with a pain reduction 
of at least 50% (Tramer and Walder, 2005)) was found to be 3.9 (95% CI: 2.3 – 11.5) 
for irritable nociceptor and 13.0 (95% CI: 5.2 - ∞) for non-irritable nociceptor. Using 
the original data provided by the principal investigators, the cohort underwent the 
individual algorithm to determine each patient’s cluster-based sensory phenotype. 
Based on mechanistic assumptions for the phenotypes identified in the previous 
steps, a hypothesis was formed which phenotype would respond to oxcarbazepine 
treatment. The treatment outcome was compared between cluster-based phenotypes 
and irritable/non-irritable nociceptor phenotyping, to analyze whether cluster-based 
phenotyping is similarly effective as (and non-inferior to) irritable/non-irritable 
nociceptor phenotyping as predictor for effectiveness of oxcarbazepine. 
Three metrics were applied to show cluster-based phenotype-specificity of 
oxcarbazepine-related pain relief and to compare treatment prediction between 
phenotyping methods (cluster-based vs. irritable/non-irritable nociceptor): 
- Treatment-phenotype interaction in a mixed effects model with pain relief as 
dependent variable, treatment (placebo/verum) and phenotype as fixed 
effects, patient as random effect and baseline pain as covariate, similar to the 
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model in the published study (Demant et al., 2014). This model was tested for 
both deterministic and probabilistic phenotyping. 
- Mean pain reduction in the verum phase. The pain reduction between baseline 
and week six in the verum phase for IN patients and patients with a cluster-
based phenotype that indicates effectiveness of oxcarbazepine was compared 
(two-tailed t-test). Cluster-based phenotyping was considered effective in case 
of a non-significant test or a significant test in combination with higher mean 
pain relief in the cluster-based phenotype compared to IN (non-inferiority). 
- Number-needed-to-treat. The NNT was calculated for the cluster-based 
phenotype along with its 95% confidence interval (Tramer and Walder, 2005). 
Cluster-based phenotyping was considered effective in case of a lower NNT in 
the cluster-based phenotype compared to IN or a higher NNT with CIs 
overlapping between the NNTs for IN and cluster-based phenotyping (non-
inferiority). 
2.8 Sample size recommendations 
[The following section has been taken in parts and modified from (Vollert et al., 
2017a).] 
If a new drug would be tested for efficacy in a phenotype-stratified subgroup with 
neuropathic pain of any single etiology, this would only be feasible if said phenotype 
appears in a relevant frequency within this etiology. To show how frequent these 
phenotypes are across three common etiologies of neuropathic pain, we applied the 
algorithm to patients suffering from neuropathic pain due to diabetic polyneuropathy, 
peripheral nerve injury or post-herpetic neuralgia from the databases of our previous 
studies (Maier et al., 2010; Demant et al., 2014; Demant et al., 2015; Themistocleous 
et al., 2016; Baron et al., 2017). 
Based on the frequencies found in the clinical entities, we calculated the size of a 
group of patients that need to be screened with either full or simplified phenotyping to 
find a sub-population large enough to perform a trial that still reaches a power of 80% 
for an effect size of 0.3, 0.5 and 0.7 at an alpha-level of 0.05, for a crossover and 
parallel design. The sample sizes presented in this thesis are examples and can be 
tailored to the needs of any planned RCT. We recommend the usage of the free 
software G*Power (Faul et al., 2007), but many other statistical packages provide 
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similar tools. The following information is required before starting: alpha-level (usually 
0.05), power (usually 0.8, 0.9 or 0.95), test family (usually t-test for independent 
(parallel design) or dependent (crossover design) means, or chi-squared for 
dichotomous outcome), and the estimated effect size in the phenotype of interest. 
Effect sizes are related to mean treatment effect and standard deviation between 
treatment response, e.g., a mean effect of 2 on a 0-10 NRS scale with a standard 
deviation of 4 corresponds to an effect size 0.5, a mean effect of 3.5 with a standard 
deviation of 5 an effect size of 0.7, and a mean effect of 1 with a standard deviation 
of 3 corresponds to an effect size of 0.3, and many other combinations are possible. 
With this information, the size of the subgroup of patients with the phenotype of 
interest that needs to be included can be calculated. To determine the size of the 
overall population which needs to be screened to find a subgroup of the calculated 
size, divide the subgroup size by the frequency of the phenotype in the etiology of 
interest as presented in the results section, in regard to the algorithm used 
(deterministic / probabilistic) and the phenotyping protocol (full / simplified). 
2.9 Subgrouping human surrogate models 
Human surrogate models were analyzed for patterns using a two-way strategy: 
1. A hypothesis-free cluster analysis was applied, using the protocol as defined 
for the cluster analysis in patients suffering from neuropathic pain (see 2.6). 
2. Since, unlike in the analysis of patients, for some human surrogate models, 
mechanisms are clearly described, as an additional means of subgrouping, a 
pattern-based individual algorithm using the method as developed based on 
patients suffering from neuropathic pain (see 2.7) was applied. This algorithm 
was in this case based on six surrogate models with a clearly described 
mechanism (A-fiber block and topical lidocaine for nerve block, topical 
capsaicin or UVB radiation for primary hyperalgesia, and i.d. capsaicin 
injection and cutaneous HFS for secondary hyperalgesia). 
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2.10 Patients in heuristic and mechanistic phenotypes 
To analyze similarities between the mechanistic sensory subgroups described above 
and the sensory phenotypes found by hypothesis-free pattern searching methods in 
patients suffering from neuropathic pain, the patients suffering from neuropathic pain 
underwent the algorithm from 2.9 and the result was compared to each patient’s 
sensory phenotype as determined using the algorithm developed for patients in 2.7.  
Agreement between algorithms was assed using Cohen’s Kappa (Fleiss et al., 2003). 
We then applied a probabilistic sorting algorithm to estimate the prevalence of the 
three presumed mechanisms in this cohort of patients; this allows each patient to be 
assigned to more than one mechanism. 
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3 RESULTS 
3.1 Patients and participants 
Patients and participants for the various analyses were not identical, and are 
therefore described briefly below. 
3.1.1 Patients 
Essential basis of all analyses of patients was the European cohort, formed for the 
cluster analysis in patients (Baron et al., 2017). This cohort comprises n = 902 
patients with peripheral neuropathic pain. Formation of this cohort is shown in Figure 
1.  
For the analysis of heterogeneity, a sub-collective of this cohort was formed: only 
data from centers which provided at least ten patients with painful polyneuropathy 
and ten patients with painful peripheral nerve injury were included. These ten centers 
provided 217 patients with painful PNP and 150 patients with painful PNI. 
For the validation set of the cluster analysis in patients, a second cohort was formed 
from patients that were included by the DFNS after the closure of the initial database 
(Maier et al., 2010) and in the IMI for pharmacological studies (Demant et al., 2014; 
Demant et al., 2015). This group comprised n = 233 patients with peripheral 
neuropathic pain due to polyneuropathy, peripheral nerve injury or post-herpetic 
neuralgia. 
For estimating frequency of phenotypes in etiologies of neuropathic pain and 
suggesting sample sizes for phenotype-stratified studies, the European cohort (n = 
902) and the validation cohort (n = 233) were merged with data from the PiNS cohort 
(n = 209). From the resulting patient group, all patients with painful peripheral nerve 
injury (n = 335), painful diabetic polyneuropathy (n = 151), and painful post-herpetic 
neuralgia (n = 97) were extracted. 
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Figure 1: CONSORT flowchart of data inclusion for the European cohort. CRPS: Complex Regional 
Pain Syndrome, DB: database. From (Baron et al., 2017). 
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3.1.2 Healthy participants 
For the analysis of heterogeneity and for separation of patients and healthy 
participants in the individual sorting algorithm, QST data from n = 188 healthy 
participants provided for ensuring quality control (Vollert et al., 2015) by ten 
European centers was included (Vollert et al., 2016a). 
3.1.3 Human surrogate models 
Many participants were tested more than once under various models, so the number 
of participants is less meaningful than the number of QSTs under surrogate models, 
which will therefore be referred to subsequently. A total of n = 657 QSTs under 
surrogate models could be included (see Table 1). 
 
model n 
Gender: 
n (%) female 
Age: 
mean (range) 
participating centers 
nerve block 
A fiber block 24 12 (50%) 25 (21 - 39) Kiel, Mannheim 
Topical lidocaine 41 20 (49%) 34 (19 - 69) Bochum 
primary hyperalgesia 
Topical capsaicin 273 147 (53%) 25 (15 - 75) 
Bochum, Frankfurt, 
Mannheim 
UVB 158 51 (32%) 24 (19 - 42) Frankfurt, Mannheim 
secondary hyperalgesia 
Capsaicin injection 36 19 (53%) 32 (23 - 68) Kiel, Mannheim, Munich 
Cutaneous HFS 12 3 (25%) 36 (24 - 57) Mannheim 
mixed 
Topical capsaicin, secondary 
hyperalgesia 
37 15 (41%) 24 (19 - 39) Mannheim 
UVB, secondary 
hyperalgesia 
22 0 (0%) 24 (24 - 24) Mannheim 
Muscular HFS 15 7 (47%) 24 (19 - 27) Mannheim 
Topical menthol 11 0 (0%) 25 (23 - 28) Kiel 
Topical lidocaine + topical 
capsaicin 
28 17 (61%) 30 (20 - 75) Bochum 
 
Table 1: Participants under human surrogate models of neuropathic pain included in the analysis. 
HFS: High Frequency Stimulation, UVB: Ultraviolet Radiation B. From (Vollert et al., 2017b). 
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3.2 Analysis of heterogeneity 
[The following section has been taken in parts and modified from (Vollert et al., 
2016a).] 
The forest plots for healthy participants, patients with polyneuropathy and peripheral 
nerve injury are shown in Figure 2 for each of the 11 normally distributed QST 
parameters, each of the 10 centers and mean effect. The forest plots show for each 
center, QST parameter and separately for healthy participants, PNP and PNI a center 
specific mean of each QST parameter, along with its 95% confidence interval. These 
confidence intervals indicate how individual and center-specific variance relate to 
each other: broader confidence intervals indicate high variance within centers that is 
not similar between all centers, narrow confidence intervals indicate high 
homogeneity within centers or variance that is similar between all centers. 
The corresponding I² values and their confidence intervals can be found in Table 2. 
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Figure 2: Forest plot of center-specific and overall mean QST z-values with 95% confidence intervals 
for healthy participants (left graph), patients with polyneuropathy (middle graph) and peripheral nerve 
injury (right graph). Note that confidence intervals are not equal to standard deviation or standard error 
of the data of each center. *model identified no center-specific mean, therefore only the overall mean 
and confidence interval is shown. All values represent the overall mean with 95% confidence interval. 
From (Vollert et al., 2016a). 
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3.2.1 Healthy participants 
All center-specific mean z-values were found to be well within the normal range of 0 ± 
1.96, the mean z-values per parameter are within 0 ± 0.20, with two exceptions: TSL 
(-0.26, 95% CI: -0.62; 0.10) and MPT (0.37, 95% CI: -0.01; 0.75). The overall mean 
z-value of all parameters and centers was found to be exactly 0.00. The 95% 
confidence intervals varied in width between 0.5 and 1.4, with a mean of 0.9. Broad 
confidence intervals indicate a high degree of individual variance within centers that 
is not found between all centers (i.e. the center-specific mean is uncertain). Inclusion 
of more participants per center might reduce the influence of this effect. In the given 
data, the largest part of variance is of individual origin, not between centers, which is 
represented in the I² values in Table 2 (first column), showing a heterogeneity of 0% 
for all parameters except PPT (41.8%, 95% CI: 0.0%; 66.1%) and MDT (5.4%, 95% 
CI: 0.0%; 18.1%).  
 
 Healthy participants Polyneuropathy Peripheral nerve injury 
CDT 0.0% (0.0% - 57.0%) 0.0% (0.0% - 0.0%) 0.0% (0.0% - 73.5%) 
WDT 0.0% (0.0% - 99.9%) 0.0% (0.0% - 54.0%) 0.0% (0.0% - 71.1%) 
TSL 0.0% (0.0% - 50.8%) 0.0% (0.0% - 57.9%) 0.0% (0.0% - 77.0%) 
CPT 0.0% (0.0% - 80.0%) 0.0% (0.0% - 91.1%) 0.0% (0.0% - 50.6%) 
HPT 0.0% (0.0% - 100.0%) 0.0% (0.0% - 98.9%) 0.0% (0.0% - 79.0%) 
PPT 41.8% (0.0% - 66.1%) 0.0% (0.0% - 82.3%) 0.0% (0.0% - 58.2%) 
MPT 0.0% (0.0% - 76.5%) 0.0% (0.0% - 99.8%) 0.0% (0.0% - 76.8%) 
MPS 0.0% (0.0% - 100.0%) 0.0% (0.0% - 59.3%) 0.0% (0.0% - 69.2%) 
WUR 0.0% (0.0% - 45.3%) 0.0% (0.0% - 33.5%) 0.0% (0.0% - 0.0%) 
MDT 5.4% (0.0% - 18.1%) 0.0% (0.0% - 92.1%) 0.0% (0.0% - 56.4%) 
VDT 0.0% (0.0% - 89.1%) 0.0% (0.0% - 26.7%) 0.0% (0.0% - 0.0%) 
 
Table 2: I² Index of heterogeneity, ranging from 0% (no heterogeneity) to 100% (perfect heterogeneity) 
for all eleven normally distributed QST parameters for healthy participants (n = 188), polyneuropathy 
patients (n = 217) and patients with peripheral nerve injury (n = 150). In brackets: lower and upper 
boundary of the 95% confidence interval. All values except PPT and MDT in healthy participants are 
zero, though the confidence intervals often cover a broad range up to 100% due to the broad 
confidence intervals of center specific mean z-values. From (Vollert et al., 2016a).  
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3.2.2 Polyneuropathy 
Center specific mean z-values for detection thresholds were characterized by loss of 
thermal and mechanical detection (CDT, WDT, TSL, MDT, VDT), which is typical for 
patients suffering from polyneuropathy. Note that the small confidence intervals (esp. 
for cold and warm detection threshold) do not reflect little variation in the dataset, but 
rather that only a small part of this variation is assigned to the center, the remainder 
is assigned to individual effects (ɛ𝑖𝑗 in F(1)) that appear across centers in similar 
form. For pain thresholds, ranges of center specific mean z-values and confidence 
intervals were found to be much broader, especially for MPT and PPT. Mean z-
values scattered within the normal range of 0 ± 1.96, but very broad confidence 
intervals show that this indicates merely high individual variance between PNP 
patients rather than systematic deviation by single centers. This is represented in I² 
values indicating heterogeneity of 0% between the centers for all parameters (Table 
2, middle column).  
3.2.3 Peripheral nerve injury 
Similar as for PNP, center specific mean z-values for detection thresholds in PNI 
patients showed loss of function. Pain thresholds are mainly decreased (with HPT as 
exception), as expected for PNI patients, who often show a combination of loss of 
detection and gain of nociception. Confidence intervals are broader compared to 
PNP, indicating that a larger amount of variance is found within instead of between 
centers. For wind-up ratio and vibration detection threshold, individual variation was 
found to superimpose any possible center specific effects (𝑎𝑖 in F(1)) in patients 
suffering from PNI, so the forest plot (Figure 2, right column) presents only the overall 
mean and its confidence interval instead of center specific means for all centers (𝜇 
instead of 𝜇 + 𝑎𝑖). As almost all center specific mean z-values lie within the 
confidence intervals of each other, the I² index of heterogeneity is 0% for all 
parameters.  
3.3 Cluster analysis of patients 
[The following section has been taken in parts and modified from (Baron et al., 
2017).] 
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According to the frequency of negative silhouette widths we excluded the solutions 
with 4 - 10 clusters because they each presented at least one cluster with a negative 
mean silhouette width that indicated an artifact. Furthermore, in each of these 
solutions negative silhouettes were frequent (15 - 23%). The remaining two and three 
cluster solutions were compared with two additional, mathematically different 
clustering algorithms for the same number of clusters. Compared with agglomerative 
hierarchical cluster analysis, both 2 and 3-cluster solutions were equal according to 
the ARI criterion, but the three-cluster solution was better according to the AVI 
criterion. In comparison to the EM algorithm, the two-cluster solution failed to show 
similarity between k-means and EM clustering (ARI almost zero, AVI almost 1). Since 
the Delta-BIC also strongly preferred the three-cluster solution (Table 3), the three-
cluster solution was used for further analysis as the optimal number of clusters. The 
replication data set was also subjected to a k-means cluster analysis with k = 3. 
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n 
(cluster) 
silhouette width: comparison to hierarchical: comparison to EM: 
mean ° 
minimum 
mean per 
cluster°° 
negative 
(%)°°° 
ARI* AVI** ARI* AVI** BIC*** 
2 0.29 0.28 0.7% 0.30 0.67 0.01 0.95 0 
3 0.25 0.13 4.8% 0.30 0.56 0.22 0.69 708 
4 0.23 -0.24 14.5% 
     
5 0.20 -0.28 16.4% 
     
6 0.15 -0.10 22.6% 
     
7 0.17 -0.07 21.2% 
     
8 0.19 -0.003 16.3% 
     
9 0.19 -0.02 16.0% 
     
10 0.21 -0.06 14.7% 
     
 
Table 3: Decision on the number of clusters. Green: optimum number of clusters according to this 
criterion. °Mean silhouette width per cluster.  A value below zero indicates clusters that do not 
separate from other clusters. Measure of discriminatory power (0 to 1). 0: no discrimination, 1: 
perfectly separated clusters (high values are preferred) °°Measure of fragmentation of solution (-1 to 
+1). -1: cluster that is solely a fragment, +1: a solution that is not fragmented (solutions with values 
below zero were discarded (yellow)) °°°Measure of fragmentation of solution (0% to 100%). 0%: no 
fragmentation, 100% a completely fragmented solution (solutions with values above 10% were 
discarded (yellow)) *ARI (Adjusted Rand Index): Measure of similarity (0 to 1). 0: only random identity, 
1: perfect identity (high values are preferred) **AVI (Adjusted Variation of Information): Measure of 
dissimilarity (0 to 1). 0: no dissimilarity, 1: strong dissimilarity (low values are preferred) ***Delta-BIC 
(Bayesian Information Criterion): Measure of gain of information by increasing cluster number. If delta-
BIC > 10, the higher cluster number is recommended. Modified from (Baron et al., 2017). 
3.3.1 Sensory profiles of the three-cluster solution 
Figure 3 shows the mean z-score sensory profiles for the test data set (Fig. 3A) and 
the validation data set (Fig. 3B). In both data sets, the clusters represented similar 
percentages of patients: cluster 1 was the largest (42% in A, 53% in B), followed by 
cluster 2 (33% in A and B) and cluster 3 (24% in A, 14% in B). Sensory profiles were 
also replicated excellently. For non-nociceptive temperature sensation (CDT, WDT, 
TSL), clusters 1 and 3 exhibited pronounced deficits with mean z-scores near -2, 
while temperature sensation was essentially normal in cluster 1. This offset was 
similar for thermal pain sensitivity (CPT, HPT), but here clusters 1 and 3 exhibited 
less of a deficit, while cluster 2 exhibited significant sensory gain. Cluster 2 was 
therefore given the label "thermal hyperalgesia". For mechanical pain sensitivity 
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(PPT, MPT, MPS), the rank order between clusters was different and cluster 1 and 3 
were separated: while there was again a deficit for cluster 1, cluster 3 exhibited 
significant sensory gain. Cluster 3 was therefore given the label "mechanical 
hyperalgesia". Wind-up did not differentiate between clusters. For non-nociceptive 
touch sensation (MDT, VDT), cluster 2 was again close to normal, cluster 3 had 
some deficit, and cluster 1 exhibited the most pronounced deficit. Cluster 1 was given 
the label "sensory loss", because it was characterized by negative mean z-scores 
across all QST parameters. Dynamic mechanical allodynia (DMA) was most 
pronounced in cluster 3, which also exhibits the most pronounced hyperalgesia to 
pinprick (MPT, MPS) and blunt pressure (PPT). Paradoxical heat sensations were 
most pronounced in cluster 1, associated with diminished cold detection (CDT) but 
not cold hyperalgesia (CPT). 
 
 
Figure 3: Sensory profiles of the three-cluster solution for test and replication data sets. Sensory 
profiles of the three clusters presented as mean z scores ± 95% confidence interval for the test 
dataset (n = 902, A) and the validation dataset (n = 233, B). Note that z-transformation eliminates 
differences due to test site, gender and age. Positive z-scores indicate positive sensory signs 
(hyperalgesia), negative z-values indicate negative sensory signs (hypoesthesia, hypoalgesia). 
Dashed lines: 95% confidence interval for healthy participants (-1·96 < z < +1·96). Inserts show 
numeric pain ratings for DMA on a logarithmic scale (0-100) and frequency of PHS (0-3). Blue 
symbols: cluster 1 "sensory loss" (42% in A, 53% in B). Red symbols: cluster 2 "thermal hyperalgesia" 
(33% in A and B). Yellow symbols: cluster 3 "mechanical hyperalgesia" (24% in A, 14% in B). From 
(Baron et al., 2017). 
 
Figure 4 illustrates the distinction of the three clusters in a 2D-scatter-plot and 
histograms of those two QST parameters that exhibited the best separation of 
Results 
35 
clusters: warm detection threshold (WDT) and mechanical pain sensitivity (MPS). 
Patients in cluster 1 had loss of pinprick sensitivity, while those in cluster 3 had 
pinprick hyperalgesia. Most patients in cluster 2 had WDT within the normal range of 
±1.96 z-values, while many of clusters 1 and 3 had hypoesthesia to warmth (z-values 
below -1.96). Although the k-means cluster separation was calculated in 13-
dimensional space, this 2D-projection illustrates some of the main characteristics 
how the three clusters differ between each other. Partial overlap between clusters 
may also be due to two mechanisms present in the same patient. WDT and MPS 
were therefore chosen for simplified phenotyping subsequently. 
 
 
Figure 4: Cluster separation projected onto two-dimensional space. Histograms and scatter plot of the 
two QST-parameters that gave the best cluster separation: warm detection threshold (WDT) and 
mechanical pain sensitivity (MPS). Blue: cluster 1 "sensory loss" (n=381 patients), red: cluster 2 
"thermal hyperalgesia" (n=302 patients), yellow: cluster 3 "mechanical hyperalgesia" (n=219 patients). 
Circles indicate centroids of each cluster. Modified from (Baron et al., 2017). 
 
3.3.2 Patient characteristics of the three clusters 
The patients´ gender and mean age as well as pain intensity did not differ between 
the three groups (Table 4). Depressive symptoms occurred significantly more 
frequently in the “sensory loss” cluster. Spontaneous pain described by the patients 
as "stabbing" was comparable across the clusters but "burning" pain was significantly 
less frequent in the “thermal hyperalgesia” cluster. 
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 sensory loss thermal hyperalgesia 
mechanical 
hyperalgesia 
n (%) 381 (42%) 302 (33%) 219 (24%) 
age 59 ± 14 56 ± 14 59 ± 15 
female 169 (39%) 152 (35%) 108 (25%) 
depression 104 (47%) * 69 (31%) 49 (22%) 
pain intensity 6.1 ± 3.1 5.8 ± 3.2 6.1 ± 3.0 
burning pain 4.5 ±3.4 4.3 ± 3.3 5.1 ± 3.2 * 
stabbing pain 4.7 ± 3.2 4.3 ± 3.2 5.0 ± 3.0 
sensory profile    
sensory loss touch, thermal, pain none mostly thermal 
hyperalgesia none mostly cold and heat mostly pressure and pin 
DMA little little much 
PHS much little little 
mechanisms    
sensory loss small and large fibers - mostly small fibers 
hyperalgesia - 
mostly peripheral 
sensitization 
mostly central 
sensitization 
ongoing pain 
ectopic activity in 
damaged nociceptors or 
CNS 
spontaneous activity in 
surviving nociceptors 
(ectopic?) activity in 
nociceptors 
 
Table 4: Cluster characteristics. *p < 0.05. From (Baron et al., 2017). 
 
According to the published DFNS reference data, each QST parameter in each 
patient can be individually rated as within or outside of the 95% confidence interval of 
variability in healthy age- and gender-matched subjects. This analysis is presented in 
Figure 5. Of patients in cluster 1 ("sensory loss"), more than 50% had significant non-
nociceptive sensory loss on an individual basis. Paradoxical heat sensation occurred 
in 40% and sensory loss for pain sensitivity was also prevalent, although at less than 
50%.  
Patients of cluster 2, in contrast, exhibited hardly any sensory loss (except for touch 
in about 20% of patients), but significant proportions of patients with hyperalgesia to 
various stimuli. Cold and heat hyperalgesia were only significant for this cluster, but - 
probably at least partly due to the substantial variability of CPT and HPT in healthy 
participants - all percentages were clearly below 50%.  
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Patients of cluster 3 were characterized by combination of loss of detection of non-
nociceptive stimuli and hyperalgesia to noxious stimuli. However, in contrast to 
cluster 1 the sensory loss was more pronounced for small fiber function, i.e. 
diminished temperature perception but relatively preserved tactile perception, and 
hyperalgesia was only present for mechanical stimuli. DMA was present in the vast 
majority of these patients.  
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Figure 5: Frequencies of abnormal QST findings for the test dataset (n = 902). Each column gives the 
percentage of patients with abnormal findings for that particular QST parameter (outside the 95% 
confidence interval of healthy participants). Positive values indicate positive sensory signs 
(hyperalgesia), negative values indicate negative sensory signs (hypoesthesia, hypoalgesia). Dashed 
lines: Expected value for healthy participants (±2.5%). A: cluster 1 "sensory loss" (n=381 patients), B: 
cluster 2 "thermal hyperalgesia" (n=302 patients), C: cluster 3 "mechanical hyperalgesia" (n=219 
patients). Significant compared to expected value (2.5%) on * p < 0.05, ** p < 0.01, *** p < 
0.001. From (Baron et al., 2017). 
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3.3.3 Distribution of clusters across etiologies 
Figure 6 illustrates that in principle all three clusters were distributed across all four 
etiologies, demonstrating that the sensory signs of neuropathic pain that are 
produced by these etiologies overlap considerably. Each of the different etiologies, 
however, showed a characteristic pattern of sensory profiles: In PNI, patients with 
“thermal hyperalgesia” were significantly more frequent (40.1%) than patients with 
other sensory profiles. In PNP and RAD, “sensory loss” occurred in 51.8% and 42.7% 
of cases, respectively. Patients with PHN were concentrated in the “mechanical 
hyperalgesia” cluster (46.6%). 
 
Figure 6: Distribution of the three clusters within each neuropathic pain etiology. Blue bars: cluster 1 
"sensory loss" (n=381 patients), red bars: cluster 2 "thermal hyperalgesia" (n=302 patients), yellow 
bars: cluster 3 "mechanical hyperalgesia" (n=219 patients). Cluster 1 was most frequent in 
polyneuropathy, cluster 2 in peripheral nerve injury and radiculopathy, and cluster 3 in post herpetic 
neuralgia. From (Baron et al., 2017). 
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3.4 Individual sorting algorithm 
[The following section has been taken in parts and modified from (Vollert et al., 
2017a).] 
3.4.1 Sorting algorithm 
The sorting algorithm was based on the means and standard deviations for each 
phenotype identified in the cluster analysis (Table 5). 
  
 
sensory loss 
(μ (σ)) 
thermal 
hyperalgesia  
(μ (σ)) 
mechanical 
hyperalgesia 
(μ (σ)) 
healthy 
participants  
(μ (σ)) 
CDT -2.42 (1.16) -0.47 (1.04) -2.03 (1.17) 0.00 (1.00) 
WDT -1.96 (0.96) -0.25 (0.97) -2.01 (1.14) 0.00 (1.00) 
TSL -2.23 (0.92) -0.45 (0.93) -2.10 (0.93) 0.00 (1.00) 
CPT -0.56 (0.81) 0.59 (1.09) -0.15 (1.01) 0.00 (1.00) 
HPT -1.20 (0.87) 0.78 (1.45) -0.67 (1.07) 0.00 (1.00) 
PPT -0.53 (1.56) 0.34 (1.56) 1.09 (2.02) 0.00 (1.00) 
MPT -1.60 (1.23) 0.42 (1.56) 0.86 (1.55) 0.00 (1.00) 
MPS -1.14 (0.81) 0.49 (1.35) 1.31 (1.41) 0.00 (1.00) 
WUR 0.13 (1.04) -0.01 (1.03) 0.21 (1.18) 0.00 (1.00) 
MDT -3.08 (4.94) -0.91 (2.46) -1.73 (2.48) 0.00 (1.00) 
VDT -2.88 (2.70) -1.02 (1.84) -1.18 (2.02) 0.00 (1.00) 
PHS 0.72 (0.96) 0.63 (0.93) 0.44 (0.83) 0.00 (1.00) 
DMA 0.24 (0.69) 1.67 (1.21) 0.54 (1.04) 0.00 (1.00) 
 
Table 5: Mean QST z-values (μ) and standard deviations (σ, in brackets) for each of the 13 QST 
parameters separately for each of the three phenotypes. Values for healthy participants follow the 
definition of z-values: mean = 0 and standard deviation = 1. PHS is coded as pseudo-normally 
distributed with 0 = absence and 2 = presence, DMA is coded pseudo-normally distributed with 0 = 
absence, 2 = 0-1 (on a 0-100 numerical rating scale), and 3 = 1-100. From (Vollert et al., 2017a). 
 
Individual allocation replicates the original cluster analysis (Baron et al., 2017) in 81% 
of the cases for the complete QST protocol using 13 parameters and in 76% of the 
cases using simplified phenotyping (only via WDT and MPS). Cohen’s kappa 
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coefficient of agreement (scale: 0 = random classification, 1 = perfect agreement 
between methods) was 0.72 for the complete protocol and 0.63 for simplified 
phenotyping, both values may be categorized as “good”, although no universal 
guideline for interpreting Cohen’s kappa exists (Fleiss, 1973). Most common shifts 
were former sensory loss or thermal hyperalgesia to mechanical hyperalgesia (14% 
and 17%, respectively), and least common shift was former sensory loss to thermal 
hyperalgesia (<1%). Patient shift between phenotypes is shown in Table 6. 
 
 
cluster 
sensory loss  
n = 381 
thermal 
hyperalgesia  
n = 302 
mechanical 
hyperalgesia  
n = 219 algorithm  
sensory loss  
n = 356 (356) 
325 (301) 15 (29) 16 (26) 
thermal hyperalgesia  
n = 267 (282 
3 (34) 235 (219) 29 (29) 
mechanical hyperalgesia  
n = 279 (264) 
53 (46) 52 (54) 174 (164) 
 
Table 6: Crosstabulation of dominant phenotype identified using cluster analysis vs. the proposed 
new, individualized algorithm (rows) for full and simplified phenotyping (in brackets). Overall, both 
classifications revealed a strong concordance of solutions (81% of the cases, 76% for simplified 
phenotyping using only warm detection threshold and mechanical pain sensitivity). From (Vollert et al., 
2017a). 
3.4.2 Discrimination analysis against healthy participants 
The ROC analysis for discrimination of patients against healthy participants is shown 
in Figure 7. The ROC-AUC value (scale: 0.5 – 1, 0.5: no discriminatory power, 1: 
perfect discrimination) for separating patients with neuropathic pain and healthy 
participants using the probability for being healthy was found to be 0.915 (95% CI: 
0.898 – 0.932), indicating high discriminatory power. For simplified phenotyping, 
discriminatory power was significantly lower (0.785, 0.753 – 0.815). The Youden-
Index was found to be highest at a probability of 64% - i.e., each subject with a 
probability value below 64% should be considered as a patient, and when above 
64% as being healthy. For simplified phenotyping, the highest Youden-Index was 
found at a very similar value of 63% with similar sensitivity (74%) but very reduced 
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specificity (72%). Due to the high similarity of cut-offs, 64% was used for both full 
protocol and simplified phenotyping. 
 
Figure 7: ROC (Receiver Operating Characteristics) analysis the discriminatory power of the healthy 
probability to separate between patients with neuropathic pain and healthy participants. Black line: full 
sensory testing, gray line: reduced protocol, using only warm detection threshold and mechanical pain 
sensitivity. The green dotted diagonal line indicates random classification (“coin flipping”). The area 
marked by dashed lines indicates the optimum ratio of sensitivity and specificity at 64% (reduced 
phenotyping: 63%) probability for being healthy. From (Vollert et al., 2017a). 
 
Individual probabilities for each phenotype for patients and healthy participants are 
plotted in Figure 8. Clinically, abnormal QST values have been defined as outside 
95% of the values found in healthy participants per parameter. As the QST protocol 
covers eleven normally distributed parameters, the chance of finding at least one 
abnormal parameter in the profile of a healthy participant is almost 50% (Vollert et al., 
2015): 
𝐹(6):      𝑝(ℎ𝑒𝑎𝑙𝑡ℎ𝑦|𝑎𝑏𝑛𝑜𝑟𝑚𝑎𝑙) =  ∑(
11
𝑘
) 0.05𝑘0.9511−𝑘 ≅ 43% 
11
𝑘=1
 
 
Using the defined threshold, this probability could be reduced to 6% (94% of healthy 
participants detected correctly), sensitivity in detecting patients was 78% (i.e., 22% of 
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patients with neuropathic pain have a sensory profile with a probability for being 
healthy above 64%).  
 
 
 
Figure 8: Phenotype probabilities and probability of being healthy for n = 902 patients with neuropathic 
pain and n = 188 healthy participants. Grey line: probability for being healthy, blue line: sensory loss, 
red line: thermal hyperalgesia, yellow line: mechanical hyperalgesia. Subjects on the x-axis are sorted 
by their individual probability of being healthy. Dotted line: a phenotype with a probability over 64% 
should be considered relevant in the individual patient. From (Vollert et al., 2017a). 
3.4.3 Deterministic and probabilistic algorithm 
To this point, we use a deterministic approach, i.e. each patient is allocated to exactly 
one phenotype. It is, however, possible that a patient may be allocated to more than 
one phenotype if each phenotype represents one set of mechanisms. So, with the 
cut-off determined for healthy participants above transferred onto patients, we can 
suggest two alternative versions of the algorithm, a deterministic one: 
1. Calculate F(5) for each of the 13 QST parameters. Use μ and σ from Table 5 
for healthy.  
2. Average the 13 probabilities. The resulting value is the probability for this 
patient to show a healthy profile. 
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3. Repeat steps 1 and 2, using μ and σ from Table 5 for sensory loss, thermal 
hyperalgesia, and mechanical hyperalgesia. 
4. Allocate the patient to the phenotype with the highest probability value. 
And a probabilistic version, where steps 1 – 3 remain identical and step four is 
exchanged with: 
4. Sort the patient to all phenotypes with a probability above 64%. If the only 
probability over 64% is for being healthy or no phenotype reaches a probability 
of 64%, the patient should be excluded. 
These two versions were used for all analyses below and are presented alongside. 
The simplified version of the algorithm is the same, except in step 1, only WDT and 
MPS are used instead of all 13 QST parameters, as these parameters have shown to 
explain the largest part of variability between the three phenotypes in our previous 
analysis (Baron et al., 2017).  
3.4.4 Effectiveness for treatment with oxcarbazepine 
Oxcarbazepine is a sodium channel blocker acting at the endings of small peripheral 
nerves, so it is assumed that it would be inferior as pain medication for patients 
suffering from deafferentation-related neuropathic pain. Therefore, based on the 
mechanistic assumptions from Table 4, oxcarbazepine should be more effective in 
the “thermal hyperalgesia” phenotype in comparison to the “sensory loss” and 
“mechanical hyperalgesia” phenotype, which both present significant loss of thermal 
detection, hinting towards loss of small fiber function. Within a cohort of n = 83 
patients suffering from peripheral neuropathic pain whose pain relief after placebo 
and oxcarbazepine treatment is known (Demant et al., 2014), n = 32 patients 
presented the thermal hyperalgesia phenotype when the deterministic version of the 
algorithm was applied. In the probabilistic version, n = 39 patients showed a relevant 
probability over 64% for the thermal hyperalgesia phenotype. Overlap between 
deterministic and probabilistic “thermal hyperalgesia” phenotype and the “irritable 
nociceptor” phenotype used in the original study is shown in Table 7. 
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 deterministic  
thermal hyperalgesia 
probabilistic  
thermal hyperalgesia   
all patients (n = 83) 32 39 
irritable nociceptor (n = 31) 24 22 
non-irritable nociceptor (n = 52) 12 17 
 
Table 7: Crosstabulation of deterministic and probabilistic identification of thermal hyperalgesia 
phenotype in relation to irritable and non-irritable nociceptor phenotype in (Demant et al., 2014). 
 
Mean pain reduction in the verum phase in the subgroup of patients with “irritable 
nociceptor” phenotype of the original study (n = 31) was 1.4 (95% CI: 0.7 – 2.8, NRS 
0 - 10). Mean pain reduction under oxcarbazepine was 1.0 (95% CI: 0.5 – 2.0; 
treatment-phenotype interaction: f = 3.384 (p = 0.020); p = 0.437 in comparison to the 
original “irritable nociceptor” group) for the deterministically phenotyped subgroup 
and 1.1 (95% CI: 0.6 – 2.3; treatment-phenotype interaction: f = 3.431 (p = 0.066); p 
= 0.475 in comparison to the original “irritable nociceptor” group) for the subgroup 
identified with the probabilistic algorithm.  
The number-needed-to-treat was 3.9 (95% CI: 2.3 – 11.5) in the IN subgroup, 6.2 
(95% CI: 3.3 – 122.1) in the subgroup identified by the deterministic algorithm, and 
6.7 (95% CI: 3.7 – 24.6) in the subgroup identified by the probabilistic algorithm.  
Overall, both versions of the algorithm provided a subgroup in which oxcarbazepine 
was only to a non-significant degree less effective than the initially used “irritable 
nociceptor” classification. The treatment-phenotype interaction variable in the mixed-
effects model was only significant for the deterministic phenotyping, not the 
probabilistic phenotyping, but it should be stated that the variance found between the 
three subgroups is well within the margin of random sampling error, showing that 
cluster-based phenotyping is non-inferior to “irritable nociceptor” phenotyping. 
3.5 Frequency of phenotypes in clinical entities 
[The following section has been taken in parts and modified from (Vollert et al., 
2017a).] 
Results 
46 
An overview of the frequency of each phenotype across the etiologies, full or 
simplified phenotyping and deterministic and probabilistic algorithm is presented in 
Table 8, details in the chapters below. Frequency of phenotypes and overlap 
between phenotypes for each clinical entity for the full protocol is displayed in Venn 
and bar diagrams in Figure 9.  
 
Phenotyping protocol: full simplified 
Algorithm: deterministic probabilistic deterministic probabilistic 
Diabetic polyneuropathy (n = 151) 
Healthy profile 4% 14% 4% 12% 
Sensory loss 64% 82% 61% 64% 
Thermal hyperalgesia 13% 33% 9% 20% 
Mechanical hyperalgesia 19% 75% 26% 36% 
Peripheral nerve injury (n = 335) 
Healthy profile 8% 19% 14% 22% 
Sensory loss 24% 29% 26% 22% 
Thermal hyperalgesia 31% 44% 24% 33% 
Mechanical hyperalgesia 37% 52% 36% 36% 
Post-herpetic neuralgia (n = 97) 
Healthy profile 6% 19% 9% 20% 
Sensory loss 20% 22% 23% 12% 
Thermal hyperalgesia 30% 39% 28% 35% 
Mechanical hyperalgesia 44% 49% 40% 34% 
 
Table 8: Frequency of each phenotype in diabetic polyneuropathy, peripheral nerve injury and post-
herpetic neuralgia, separately for the deterministic and probabilistic algorithm, and for full and 
simplified phenotyping. From (Vollert et al., 2017a). 
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3.5.1 Deterministic 
Most common phenotype in diabetic polyneuropathy was sensory loss (n = 96, 64%), 
while in 20 (13%) patients thermal hyperalgesia and in 29 (19%) patients mechanical 
hyperalgesia was the dominant phenotype. Six (4%) patients presented a profile 
most similar to healthy participants.  
In peripheral nerve injury, mechanical and thermal hyperalgesia were frequent (n = 
125, 37% and n = 105, 31%, respectively), while sensory loss was less prominent (n 
= 82, 24%). Twenty-three (7%) patients showed highest probability for a healthy QST 
profile. Post herpetic neuralgia was mostly characterized by the mechanical 
hyperalgesia phenotype (n = 43, 44%), followed by thermal hyperalgesia (n = 29, 
30%) and sensory loss (n = 19, 20%). Six (6%) patients had the highest probability 
for a QST profile similar to healthy participants. 
3.5.2 Probabilistic 
Of the diabetic polyneuropathy cohort, 4 patients (3%) were not sorted to any 
phenotype nor healthy and had to be excluded. Twenty-one (14%) patients showed a 
relevant probability for the healthy profile, all of them were additionally assigned to a 
phenotype. Most common phenotype (n = 124, 82%) was sensory loss, while in 50 
(33%) patients thermal hyperalgesia and in 113 (75%) patients mechanical 
hyperalgesia was a prominent phenotype, the latter in significant difference to the 
deterministic algorithm (19%). Twenty-seven patients (18%) were possible to assign 
to all three phenotypes and 86 (57%) to two phenotypes, with the largest overlap 
between sensory loss and mechanical hyperalgesia.  
In peripheral nerve injury, 70 (21%) patients were not assigned to any phenotype and 
2 (<1%) only to the healthy profile, these patients were all excluded. Sixty-three 
(19%) patients were assigned to the healthy profile and at least one additional 
phenotype. Overall, mechanical hyperalgesia was most frequent, followed by thermal 
hyperalgesia (n = 173 (52%) and n = 146 (44%), respectively), while sensory loss 
was less prominent (n = 98, 29%).  17 patients (5%) were allocated to all three 
phenotypes, 120 (36%) to two phenotypes, with sensory loss and thermal 
hyperalgesia showing the least overlap.  
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Figure 9: Venn and bar diagrams of phenotype frequency and overlap between phenotypes for A) 
diabetic polyneuropathy, B) peripheral nerve injury and C) post-herpetic neuralgia. Bars are to scale, 
size of the circles and overlaps is illustrative, not to scale. Grey: healthy, blue: sensory loss, red: 
thermal hyperalgesia, yellow: mechanical hyperalgesia.  First bar (DET): deterministic algorithm (adds 
to 100%), three subsequent bars: probabilistic approach (a patient may be allocated to more than one 
phenotype, percentages are not additive). H: healthy, SL: sensory loss, TH: thermal hyperalgesia, MH: 
mechanical hyperalgesia. From (Vollert et al., 2017a). 
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In post-herpetic neuralgia, 29 (30%) patients were not possible to assign to any 
phenotype, these patients were excluded. Eighteen patients showed a relevant 
probability for a healthy profile, all of them were additionally sorted to at least one 
phenotype. Overall, patients with post-herpetic neuralgia were mostly characterized 
by the mechanical hyperalgesia phenotype (n = 48, 49%), followed by thermal 
hyperalgesia (n = 38, 39%) and sensory loss (n = 21, 22%). Six patients (6%) were 
possible to assign to all three phenotypes, 27 (28%) to two phenotypes, with the 
largest overlap between thermal and mechanical hyperalgesia.  
3.5.3 Simplified phenotyping 
Overall, 57% of patients with diabetic polyneuropathy, 62% of patients with peripheral 
nerve injury and 58% of patients with post-herpetic neuralgia were sorted into the 
same phenotype allocated when the full protocol was applied. The sensitivity of the 
simplified algorithm, however, is dependent on a combination of phenotype of 
interest and the clinical entity under study: in diabetic polyneuropathy, 74% of 
sensory loss patients were correctly identified, but only 48% of patients with thermal 
hyperalgesia and even less 43% of patients with mechanical hyperalgesia. In 
patients with peripheral nerve injury, allocation accuracy was more balanced between 
phenotypes (75% for sensory loss, 60% for thermal hyperalgesia, 64% for 
mechanical hyperalgesia). In patients with post-herpetic neuralgia, sensitivity was 
very low for sensory loss (24%), and better for thermal (76%) and mechanical 
hyperalgesia (56%).  
3.6 Sample size recommendations 
[The following section has been taken in parts and modified from (Vollert et al., 
2017a).] 
Estimated sample sizes for parallel or crossover design, the three phenotypes and 
the three etiologies of neuropathic pain are presented in Table 9 for both full and 
simplified phenotyping, applying the deterministic or probabilistic version of the 
algorithm.  
In summary, for parallel study design, either the estimated effect size of the treatment 
needs to be high (>0.7) or only phenotypes that are frequent in the clinical entity 
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under study can realistically be performed. For crossover design, populations under 
200 patients need to be screened for all phenotypes and clinical entities with a 
minimum estimated treatment effect size 0.5.  
Low sensitivity of the simplified algorithm is linked to low frequency of certain 
phenotypes (esp. thermal hyperalgesia in diabetic polyneuropathy and sensory loss 
in post-herpetic neuralgia), leading to higher numbers of patients that need to be 
screened. 
 
Study design parallel crossover 
Effect size 0.3 0.5 0.7 0.3 0.5 0.7 
Diabetic polyneuropathy 
Sensory loss 
550 (577) 
429 (550) 
200 (210) 
156 (200) 
106 (111) 
83 (106) 
141 (148) 
110 (141) 
53 (56) 
41 (53) 
30 (31) 
23 (30) 
Thermal 
hyperalgesia 
2708 (3911) 
1067 (1760) 
985 (1422) 
388 (640) 
523 (756) 
206 (340) 
692 (1000) 
273 (450) 
262 (378) 
103 (170) 
146 (211) 
58 (95) 
Mechanical 
hyperalgesia 
1853 (1354) 
469 (978) 
674 (492) 
171 (356) 
358 (262) 
91 (189) 
474 (346) 
120 (250) 
179 (131) 
45 (94) 
100 (73) 
25 (53) 
Peripheral nerve injury 
Sensory loss 
1467 (1354) 
1214 (1600) 
533 (492) 
441 (582) 
283 (262) 
234 (309) 
375 (346) 
310 (409) 
142 (131) 
117 (155) 
79 (73) 
66 (86) 
Thermal 
hyperalgesia 
1135 (1467) 
800 (1067) 
413 (533) 
291 (388) 
219 (283) 
155 (206) 
290 (375) 
205 (273) 
110 (142) 
77 (103) 
61 (79) 
43 (58) 
Mechanical 
hyperalgesia 
951 (978) 
677 (978) 
346 (356) 
246 (356) 
184 (189) 
131 (189) 
243 (250) 
173 (250) 
92 (94) 
65 (94) 
51 (53) 
37 (53) 
Post-herpetic neuralgia 
Sensory loss 
1760 (1530) 
1600 (2933) 
640 (557) 
582 (1067) 
340 (296) 
309 (567) 
450 (391) 
409 (750) 
170 (148) 
155 (283) 
95 (83) 
86 (158) 
Thermal 
hyperalgesia 
1173 (1257) 
903 (1006) 
427 (457) 
328 (366) 
227 (243) 
174 (194) 
300 (321) 
231 (257) 
113 (121) 
87 (97) 
63 (68) 
49 (54) 
Mechanical 
hyperalgesia 
800 (880) 
718 (1035) 
291 (320) 
261 (376) 
155 (170) 
139 (200) 
205 (225) 
184 (265) 
77 (85) 
69 (100) 
43 (48) 
39 (56) 
 
Table 9: Number of patients, that need to be screened to find a sub-population with a given phenotype 
large enough to conduct a study with a power of 80% with an alpha-level of 0.05 and a given effect 
size. First row: deterministic algorithm, second row: probabilistic algorithm. Values in brackets show 
the number needed to be screened with the simplified protocol. Numbers in bold indicate that 200 or 
less patients need to be screened. From (Vollert et al., 2017a). 
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3.7 Subgrouping human surrogate models 
[The following section has been taken in parts and modified from (Vollert et al., 
2017b).] 
The analysis comprised a total of n=657 healthy subjects that participated in studies 
on human surrogate models: nine distinct models (two of them in the area of primary 
and secondary hyperalgesia) at five centers (Table 1). About 44% of subjects were 
female (291/657); gender distribution was not homogenous across models, as for the 
UVB, cutaneous HFS and menthol models predominantly males were recruited. Age 
ranges were mostly lower than in neuropathic pain populations. These factors were 
accounted for by normalizing all QST data to gender-specific and age-specific 
reference data.  
Fig. 10 shows z-profiles of the six models used for defining phenotype means. As 
human surrogate models of nerve blocks, both nerve compression and topical 
lidocaine led to substantial loss in thermal and mechanical detection thresholds (Fig. 
10A). For CDT and MDT in the A-fiber block, this loss was almost complete, reaching 
a mean z-value beyond -5, i.e. beyond five standard deviations of normal detection. 
A-fiber block was also associated with pinprick hyperalgesia and paradoxical heat 
sensations.  
As human surrogate models of primary hyperalgesia, topical capsaicin and UVB 
sunburn both induced substantial heat and mechanical hyperalgesia (Fig. 10B). Heat 
hyperalgesia was more pronounced for capsaicin, mechanical hyperalgesia more 
pronounced for UVB. Capsaicin also induced loss of cold detection and cold pain.   
As human surrogate models of secondary hyperalgesia, cutaneous HFS and i.d. 
capsaicin injection led to mechanical hyperalgesia and thermal sensory deficits (Fig. 
10C). Mechanical hyperalgesia and DMA were more pronounced in the capsaicin 
injection model.  
Table 10 compares mean z-scores normalized to published reference data of healthy 
subjects with effect sizes in intra-individual comparison to untreated control areas. 
Intra-individual comparisons mostly confirmed the patterns of negative or positive 
sensory signs of z-values, but the loss of thermal detection for i.d. capsaicin and 
cutaneous HFS (Fig. 10C) appears to be overestimated in z-values due to the non-
standard test area.  
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Figure 10: Deep sensory profiling of human surrogate models of a priori mechanisms. A: nerve blocks, 
B: primary hyperalgesia, C: secondary hyperalgesia. From (Vollert et al., 2017b). 
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CDT WDT TSL CPT HPT PPT MPT MPS WUR MDT VDT 
A-fiber block z -5.49 -1.75 -3.23 0.08 -0.41 -0.75 2.74 0.90 1.28 -6.48 0.06 
 
D -4.36 -0.29 -1.90 0.69 0.28 -0.46 2.68 1.07 0.99 -4.83 0.02 
Topical lidocaine z -2.10 -1.33 -2.31 0.09 0.56 -0.58 -0.40 -0.86 -0.37 -1.85 0.42 
 
D -1.40 -1.21 -1.69 -0.59 0.05 -0.36 -1.27 -0.99 -0.36 -0.94 0.01 
Topical capsaicin z -1.62 -0.24 -1.27 -0.72 2.79 1.06 1.29 0.61 0.21 -0.48 -0.02 
 
D -1.22 -0.32 -0.84 -0.75 2.57 0.28 0.96 0.69 0.10 -0.30 0.08 
UVB z 0.03 -0.14 -0.67 0.71 1.70 1.92 1.97 1.03 0.27 -0.16 -0.42 
 
D 1.62 -0.23 0.40 0.18 1.30 0.78 2.80 1.39 -0.96 0.63 0.42 
capsaicin i.d. z -2.57 -2.14 -2.40 0.08 -0.05 1.15 3.67 2.18 -0.13 -0.63 -1.16 
 
D -0.49 -0.22 -0.29 -0.06 0.15 0.69 2.50 1.66 -0.20 0.28 0.04 
cutaneous HFS z -2.98 -1.89 -2.49 0.48 -0.25 -0.06 1.52 0.51 0.42 -0.93 
 
 
D -0.69 -0.17 -0.40 -0.25 -0.18 0.49 0.91 0.90 -0.05 0.81 
 
2° hyperalgesia z -1.64 -1.30 -1.48 0.48 0.65 1.07 1.71 1.10 0.14 -1.51 -2.18 
topical capsaicin D -0.40 -0.44 -0.34 0.06 0.31 0.22 0.73 1.04 -0.19 0.16 0.12 
2° hyperalgesia z -0.97 0.05 -0.74 0.59 0.58 1.10 0.56 0.14 1.24 -0.89 -1.11 
UVB D 0.43 -0.02 0.30 0.07 0.33 0.10 0.73 0.41 0.05 -0.33 0.03 
muscular HFS z -0.86 0.12 -0.41 0.75 0.83 1.01 0.52 0.08 0.49 -0.99 -0.86 
 
D 0.06 -0.04 -0.07 0.21 0.07 -0.13 -0.34 -0.15 0.04 0.04 0.00 
topical menthol z -1.00 -0.72 -0.08 1.08 0.03 -0.70 1.33 0.25 -0.28 0.34 0.29 
 
D -0.63 -0.41 0.07 1.94 0.67 0.32 2.59 0.80 -0.27 0.29 0.15 
topical lidocaine  z -3.31 -1.74 -3.09 -1.23 2.08 0.26 -0.07 -0.65 -0.20 -1.30 0.49 
+ capsaicin D -2.18 -1.57 -2.49 -2.49 2.07 0.21 -0.67 -0.30 -0.14 -0.53 -0.24 
 
Table 10: z-scores and effect sizes (D) of human surrogate models. z-scores: boundaries 1.0 and 
1.96. D values boundaries above 0.5 and 0.8. From (Vollert et al., 2017b). 
 
The QST profiles of the remaining models are presented in Figure 11. Fig 11A shows 
the QST profiles of surrounding skin from two models where secondary hyperalgesia 
is either controversial (UVB) or known to be mild (topical capsaicin). While the area of 
secondary hyperalgesia of topical capsaicin displays sensory loss in the z-profile, 
these effects are much smaller in the intra-individual comparisons with untreated 
skin, again suggesting an overestimation in z-values due to the non-standard test 
area (Table 10). Topical menthol has been introduced to induce cold hyperalgesia, 
and muscle HFS to induce deep hyperalgesia (Fig. 11B); sensory changes in both 
models were mild. Fig. 11C shows a combined model of nerve block and primary 
hyperalgesia. 
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Figure 11: Deep sensory profiling of additional human surrogate models. A: secondary hyperalgesia 
surrounding topical capsaicin or UVB treated areas, B: topical menthol (cold hyperalgesia model) and 
muscle HFS (deep pain model), C: sequentially combined topical application of lidocaine and 
capsaicin. From (Vollert et al., 2017b). 
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3.7.1 Cluster analysis of human surrogate models 
Unlike for patients suffering from neuropathic pain, the cluster analysis of human 
surrogate models did not reveal meaningful results. All solutions for 2 - 9 clusters 
presented with a high count of negative silhouettes (above 10%, see Table 11), 
which indicates solutions that are mere statistical artefacts rather than separate 
clusters and had to be excluded according to the quality criteria for acceptable 
solutions in our protocol. The two clusters solution scored highest in mean silhouette 
width and ARI in comparison to hierarchical clustering, but also showed a frequency 
of negative silhouettes above the cut-off of 10%. The ten clusters solution scored 
highest in the remaining quality criteria, still, ten is a suspiciously high number 
considering that only eleven models are included. 
In addition, all solutions from 4 - 10 clusters were unstable in the k-means clustering, 
i.e. the algorithm presented various solutions in various runs instead of coming to the 
same solution for a given number of clusters, indicating various local optimum 
solutions rather than one globally optimal solution. Indices for comparison to methods 
of distinct mathematical background (hierarchical and Bayesian clustering) presented 
a similarity between methods far lower than it was the case for clustering of patients.  
Therefore, for human surrogate models, no subgrouping based on a hypothesis-free 
cluster analysis of sensory profiles can be applied.  
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n 
(cluster) 
silhouette width: comparison to hierarchical: comparison to EM: 
mean ° 
minimum 
mean per 
cluster°° 
negative 
(%)°°° 
ARI* AVI** ARI* AVI** BIC*** 
2 0.29 0.06 14.5% 0.17 0.52 0.28 0.41 0 
3 0.26 0.10 12.2% 0.17 0.47 0.23 0.45 747.25 
4 0.21 0.13 12.5% 
     
5 0.20 0.12 11.3% 
     
6 0.18 0.10 11.9% 
     
7 0.17 0.09 16.1% 
     
8 0.20 0.11 14.8% 
     
9 0.21 0.14 11.6% 
     
10 0.21 0.11 9.7% 0.20 0.21 0.23 0.22 1338.85 
 
Table 11: Decision on the number of clusters for human surrogate models. °Mean silhouette width per 
cluster.  A value below zero indicates clusters that do not separate from other clusters. Measure of 
discriminatory power (0 to 1). 0: no discrimination, 1: perfectly separated clusters (high values are 
preferred). °°Measure of fragmentation of solution (-1 to +1). -1: cluster that is solely a fragment, +1: a 
solution that is not fragmented (solutions with values below zero were discarded) °°°Measure of 
fragmentation of solution (0% to 100%). 0%: no fragmentation, 100% a completely fragmented 
solution (solutions with values above 10% were discarded) *ARI (Adjusted Rand Index): Measure of 
similarity (0 to 1). 0: only random identity, 1: perfect identity (high values are preferred) **AVI (Adjusted 
Variation of Information): Measure of dissimilarity (0 to 1). 0: no dissimilarity, 1: strong dissimilarity (low 
values are preferred) ***Delta-BIC (Bayesian Information Criterion): Measure of gain of information by 
increasing cluster number. If delta-BIC > 10, the higher cluster number is recommended.  
 
3.7.2 Pattern-based sorting algorithm 
By random number assignment, 49% of subjects from the six surrogate models with 
clearly defined mechanism (topical lidocaine, A-fiber block, topical capsaicin, UVB 
radiation, capsaicin injection and cutaneous HFS) were assigned to the training data 
set (n = 265), which defined mean values and standard deviations for the sorting 
algorithm (Table 12).  
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nerve block  
(μ (σ)) 
primary 
hyperalgesia 
(μ (σ)) 
secondary 
hyperalgesia 
(μ (σ)) 
healthy 
participants  
(μ (σ)) 
CDT -2.94 (2.36) -1.05 (1.59) -2.71 (1.07) 0.00 (1.00) 
WDT -1.36 (1.27) -0.23 (1.04) -1.87 (0.89) 0.00 (1.00) 
TSL -2.55 (1.52) -1.03 (1.12) -2.28 (0.84) 0.00 (1.00) 
CPT 0.06 (1.13) -0.12 (1.31) 0.33 (1.16) 0.00 (1.00) 
HPT 0.52 (1.23) 2.37 (1.14) -0.14 (1.24) 0.00 (1.00) 
PPT -0.63 (0.97) 1.35 (1.66) 0.63 (1.45) 0.00 (1.00) 
MPT 0.86 (1.87) 1.54 (1.08) 3.12 (0.97) 0.00 (1.00) 
MPS -0.15 (1.38) 0.71 (1.21) 1.95 (1.19) 0.00 (1.00) 
WUR 0.25 (1.29) 0.18 (1.01) 0.31 (1.15) 0.00 (1.00) 
MDT -3.24 (2.89) -0.32 (1.13) -0.80 (1.38) 0.00 (1.00) 
VDT 0.22 (1.06) -0.23 (1.93) -1.08 (1.83) 0.00 (1.00) 
PHS 0.06 (0.34) 0.81 (1.07) 1.12 (1.11) 0.00 (1.00) 
DMA 0.48 (0.86) 0.13 (0.49) 0.16 (0.54) 0.00 (1.00) 
 
Table 12: Mean QST z-values (μ) and standard deviations (σ, in brackets) for each of the 13 QST 
parameters separately for each of the three mechanistic subgroups. Values for healthy participants 
follow the definition of z-values: mean = 0 and standard deviation = 1. PHS is coded as pseudo-
normally distributed with 0 = absence and 2 = presence, DMA is coded pseudo-normally distributed 
with 0 = absence, 2 = 0-1 (on a 0-100 numerical rating scale), and 3 = 1-100. From (Vollert et al., 
2017b). 
 
Individual allocation by the deterministic sorting algorithm replicated the a priori 
assignment of surrogate models in 79% of the cases for training set and in 81% of 
the cases for the test set (remaining 279 subjects from the same surrogate models). 
Cohen’s kappa coefficient of agreement (scale: 0 = random classification, 1 = perfect 
agreement between methods) was 0.54 (95% confidence interval: 0 – 1) for the 
training set and 0.56 (95% confidence interval: 0 – 1) for the test set, both values 
may be categorized as “good”, although no universal guideline for interpreting 
Cohen’s kappa exists (Fleiss, 1973), and the confidence intervals reaching from zero 
to one indicate that the profiles are so unevenly distributed that these kappa values 
should not be overinterpreted. Most common shifts were primary or secondary 
hyperalgesia to nerve block (18% and 27%, respectively), and least common shifts 
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were nerve block to secondary hyperalgesia and secondary to primary hyperalgesia 
(both <1%). Shifts between original and algorithmic assignment is shown in Table 13. 
 
 
original 
nerve block 
primary 
hyperalgesia 
secondary 
hyperalgesia algorithm 
 
nerve block 29 / 30 4 / 2 0 / 0 
primary hyperalgesia 35 / 42 162 / 178 10 / 4 
secondary hyperalgesia 8 / 5 0 / 1 17 / 17 
 
Table 13: Crosstabulation of dominant phenotype identified using the algorithm (columns) vs. the 
original assignment (rows) for training and test dataset (in brackets). Overall, concordance of the 
algorithm to original assignment was strong (79% of the cases for the training and 81% for the test 
dataset, note that the even higher concordance for the test dataset compared to training data indicates 
a very robust effect). From (Vollert et al., 2017b). 
 
3.7.3 Deterministic and probabilistic sorting 
The z-profiles of each sensory subgroup are shown in Figure 12. Forty-one subjects 
showed a sensory profile, that was most similar to untreated healthy skin, although 
part of a surrogate model (Fig. 12A). The subjects sorted to the nerve block profile 
were mostly characterized by loss of cold and mechanical detection (CDT and MDT, 
both representing A-fiber function, Fig. 12A). Loss of vibration detection was not 
detectable, which is due to a limitation in the A-fiber block, which only affects a small 
area, while vibration can be sensed by rapidly adapting mechanoreceptors situated 
beyond this area. Primary hyperalgesia (Fig. 12B) was characterized mostly by heat 
hyperalgesia, while secondary hyperalgesia presented mostly mechanical 
hyperalgesia, and also loss of thermal detection.  
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Figure 12: Average profiles per mechanism-stratified human surrogate models. Using the deterministic 
algorithm, 657 healthy subjects that had undergone human surrogate models of chronic pain were 
sorted into one of four categories of sensory profiles. A: nerve blocks vs. healthy profiles, B. primary 
vs. secondary hyperalgesia profiles. Positive z-scores indicate positive sensory signs (hyperalgesia), 
negative z-values indicate negative sensory signs (hypoesthesia, hypoalgesia). Dashed lines: 95% 
confidence interval for healthy participants (-1.96 < z < +1.96). Inserts show numeric pain ratings for 
DMA on a logarithmic scale (0-100) and frequency of PHS (0-3).From (Vollert et al., 2017b). 
 
In the probabilistic sorting algorithm, the percentage of sensory profiles compatible 
being from normal skin increased to 187 (28%) vs. 41 (6%) in the deterministic 
version of the algorithm. The highest frequency of healthy profiles was found in 
muscular HFS and topical menthol (see Figure 13 for all frequencies per model and 
prototypic mechanistic profile), which also had the mildest sensory changes in their 
averaged QST profiles (Fig. 11B).  
QST profiles compatible with the nerve block profile increased to 352 cases (54%) in 
the probabilistic algorithm vs. 178 (27%) in the deterministic version. Apart from the 
defining models of A-fiber block and topical lidocaine, the highest frequency of the 
nerve block profile was found in cutaneous HFS and in the menthol model.  
QST profiles compatible with primary hyperalgesia increased from 380 (58%) in the 
deterministic to 470 (72%) in the probabilistic algorithm. Beyond the defining models, 
this profile was frequent in the area of secondary hyperalgesia of the UVB radiation 
model, topical menthol and muscular HFS.  
QST profiles consistent with secondary hyperalgesia were more than twice as 
frequent in the probabilistic sorting (n = 134; 20%) that in the deterministic sorting (n 
= 58; 9%). Beyond the defining capsaicin injection and cutaneous HFS, this profile 
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was only found in the area of secondary hyperalgesia of topical capsaicin in a 
relevant frequency (deterministic: 27%, probabilistic: 65%).   
 
 
 
Figure 13: Deterministic and probabilistic sorting of human surrogate models and patients suffering 
from peripheral neuropathic pain. A: compression block (n=24), B: topical lidocaine (n=41), C: topical 
capsaicin (n=273), D: UVB sunburn (n=158), E: i.d. capsaicin injection (n=36), F: electrical high-
frequency stimulation through punctate surface electrode (n=12), G: skin surrounding topical capsaicin 
(n=37), h: skin surrounding UVB sunburn (n=22),I: muscle HFS (n=15), J: topical menthol (n=11), K: 
topical lidocaine plus capsaicin (n=28), L: patients suffering from peripheral neuropathic pain (n=902). 
Deterministic sorting (DET): each profile is sorted to its best fit, probabilistic sorting: each profile is 
sorted to each mechanism for which it reaches a probability above 64%, as determined as optimal cut-
off in a ROC analysis of patients suffering from neuropathic pain and healthy subjects in (Vollert et al., 
2017b). H (grey): normal healthy skin, NB (Blue): nerve blocks, PH (red): primary hyperalgesia, SH 
(yellow): secondary hyperalgesia. From (Vollert et al., 2017b). 
 
3.8 Patients in heuristic and mechanistic phenotypes 
In 65% of the cases, patients sorted to the sensory loss phenotype were sorted to 
nerve block, patients sorted to the thermal hyperalgesia phenotype to the primary 
hyperalgesia pattern, and patients sorted to the mechanical hyperalgesia phenotype 
to the secondary hyperalgesia pattern (Table 14). This corresponded to a Cohen’s 
kappa coefficient of agreement (scale: 0 = random classification, 1 = perfect 
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agreement between methods) of 0.44 (95% CI: 0.28 - 0.60), showing a substantial 
degree of agreement (Fleiss et al., 2003). The most prominent shifts were from the 
two hyperalgesia phenotypes in the heuristic patient clustering into the mechanistic 
phenotype consistent with nerve block.  
In the probabilistic sorting (Table 14), interestingly, fewer patients were sorted to the 
nerve block profile (512 vs. 600 in deterministic sorting), while relatively more 
patients were sorted to primary (271 vs. 186 in deterministic sorting) or secondary 
hyperalgesia (198 vs. 116 in deterministic sorting). But the most prominent shift was 
still towards the profiles consistent with nerve blocks. These findings suggest the 
presence of multiple mechanisms in some of the patients. In fact, only one third of 
patients could be uniquely assigned to one of the three mechanisms. Another third of 
the patient QST profiles was consistent with multiple mechanisms (n = 282), most 
frequently a combination including the nerve block phenotype. The last third was not 
sufficiently distinct from a normal skin QST phenotype to be assigned to any 
mechanism (n = 279).  
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sensory loss 
(n = 356) 
thermal 
hyperalgesia  
(n = 267) 
mechanical 
hyperalgesia  
(n = 279)   
deterministic 
nerve block (NB, n = 600) 337 97 166 
primary hyperalgesia  
(PH, n = 186) 
6 156 24 
secondary hyperalgesia 
(SH, n = 116) 
13 14 89 
probabilistic 
NB, n = 512 202 130 180 
PH, n = 271 12 163 96 
SH, n = 198 38 26 134 
of the above: patients sorted to a single mechanism (n = 341) 
NB, n = 247 163 30 54 
PH, n = 62 1 58 3 
SH, n = 32 3 3 26 
of the above: patients sorted to multiple mechanisms (n = 282) 
NB + PH (n=116) 4 84 28 
NB + SH (n=73) 28 2 43 
PH + SH (n=17) 0 7 10 
NB + PH + SH (n = 76) 7 14 55 
patients sorted to no mechanism (n= 279) 
 150 69 60 
 
Table 14: Crosstabulation of dominant phenotype identified using the algorithm developed in patients 
(columns) vs. the algorithm developed based on surrogate models (rows) for n=902 patients. In the 
clear majority of the cases (65%, note that random assignment would be 33%) both algorithms 
concurred in the deterministic variant. From (Vollert et al., 2017b). 
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Figure 14 illustrates the similarity in QST profiles grouped either according to the 
original cluster analysis or the mechanistic sorting. While the profiles of patients 
sorted according to both algorithms are highly similar, the profiles of patients and 
surrogate models in the mechanistic sorting displays some interesting differences 
(compare Fig. 12 with Fig. 14B): patients sorted to the nerve block suffer from 
hypoalgesia, while in surrogate models pain thresholds are normal or show mild gain. 
Patients sorted to nerve block also have loss of VDT, which could not be modeled in 
the A-fiber block. For primary hyperalgesia, the models display almost no cold, but an 
isolated heat hyperalgesia, while patients show both cold and heat hyperalgesia. For 
secondary hyperalgesia, participants under surrogate models have more gain in MPT 
than in MPS, which is reversed in patients. 
 
 
 
Figure 14: Average profiles per mechanism-stratified patient group. Using the deterministic algorithm, 
902 patients with peripheral neuropathic pain (Baron et al., 2017) were sorted either according to three 
heuristic patient clusters (A) or according to three mechanistic clusters from human surrogate models 
(B). Positive z-scores indicate positive sensory signs (hyperalgesia), negative z-values indicate 
negative sensory signs (hypoesthesia, hypoalgesia). Dashed lines: 95% confidence interval for healthy 
participants (-1.96 < z < +1.96). Inserts show numeric pain ratings for DMA on a logarithmic scale (0-
100) and frequency of PHS (0-3).  From (Vollert et al., 2017b). 
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4 DISCUSSION 
Aim of the presented work was to improve usefulness of Quantitative Sensory 
Testing for application in individual diagnostics, and to establish a mechanism-related 
classification of peripheral neuropathic pain that can be used for stratification of 
clinical trials and for individual patients’ therapy. This global aim, on which pain 
researchers work since over 25 years (Fields et al., 1998; Woolf et al., 1998; 
Baumgartner et al., 2002; Baron et al., 2012; von Hehn et al., 2012; Edwards et al., 
2016), has been progressed to a substantial degree. The main findings of this work 
were: 
As a premise to using QST in multicentral clinical trials, it is crucial that examiners 
across centers, countries and languages produce comparable results. In an analysis 
of heterogeneity of patient and healthy participant data from ten European centers, 
eight countries and eight languages, it could be shown that skilled QST examiners 
are able to produce homogeneous results (Vollert et al., 2016a). The I² index of 
heterogeneity, ranging from 0% (no heterogeneity) to 100% (completely 
heterogeneous data) (Higgins and Thompson, 2002) was found to be 0% for all QST 
parameters for patients suffering from painful polyneuropathy or peripheral nerve 
injury, and 0% for healthy participants for all QST parameters except MDT (negligible 
5.4%) and PPT (substantial 41.8%). Notably, the heterogeneity is lower in patients, 
where it is crucial that centers test reproducibly. 
In a cluster analysis in 902 patients suffering from peripheral neuropathic pain, it 
could be shown that three sensory phenotypes appear across etiologies, and are 
stable across cohorts, as they are validated in a second cohort of 233 patients. 
These phenotypes are mainly characterized by  
1. Hypoesthesia, both thermal and mechanical. This phenotype is labelled 
“sensory loss”, 
2. Comparably intact sensory function, often combined with thermal hyperalgesia 
or allodynia. This phenotype is labelled “thermal hyperalgesia” and 
3. Thermal hypoesthesia, combined with mechanical hyperalgesia or allodynia, 
therefore called “mechanical hyperalgesia”. 
An algorithm that is able to assign single patients to each of these phenotypes was 
developed, validated in the original cohort and tested for its capability to separate 
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healthy participants from patients with neuropathic pain. Using this algorithm, sample 
sizes of patient groups that need to be screened to identify a phenotype-stratified 
subgroup large enough to conduct a clinical trial were calculated. These numbers 
suggest that crossover design studies are realistic for all phenotypes and the 
etiologies diabetic polyneuropathy, peripheral nerve injury and post-herpetic 
neuralgia, while parallel design studies will need very large screened populations for 
many phenotype-etiology combinations. 
To further validate mechanistic basics of the identified phenotypes, a cluster analysis 
with identical protocol was conducted in n = 657 QSTs of healthy participants under 
human surrogate models of neuropathic pain. While the cluster analysis revealed no 
sufficient results, a sorting algorithm previously validated for sensory profiles of 
neuropathic pain patients (Vollert et al., 2017a) led to reproducible sorting of 
surrogate model sensory profiles into patterns defined a priori according to known 
mechanisms in a randomized split half analysis. Sorting of 902 neuropathic pain 
patients into these mechanistic phenotypes led to a similar distribution as the original 
heuristic clustering of the same patients (Baron et al., 2017; Vollert et al., 2017b; 
Vollert et al., 2017a). 
4.1 Heterogeneity between centers 
[The following section has been taken in parts and modified from (Vollert et al., 
2016a).] 
A central goal of the consortia DFNS, IMI Europain and Neuropain was to jointly 
gather data of patients suffering from neuropathy from centers across Europe, 
assessed in a highly valid protocol for a psychophysical testing procedure with broad 
scientific and clinical applications (Rolke et al., 2006a; Backonja et al., 2013) in a 
central database. One essential premise for performing multi-center analyses is 
homogeneous, unbiased results across all centers. The presented analysis of 
heterogeneity showed that there is no evidence of systematic heterogeneity between 
the QST assessment of the ten included centers located in eight countries across 
Europe and that the data can be analyzed as a homogenous group of patients.   
The fact that these centers were able to produce highly reliable results in QST 
assessment, provided that the examiners are well trained and a strict protocol is 
applied, corresponds to previous findings in healthy participants (Rolke et al., 2006a; 
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Geber et al., 2009; Krumova et al., 2012a; Vollert et al., 2015) and patients suffering 
from painful neuropathies (Felix and Widerstrom-Noga, 2009; Geber et al., 2011). 
Still, this was the first multi-national and multi-lingual analysis of heterogeneity, 
showing that reproducible results can be achieved in bigger international consortia.  
These findings are in line with a previous study reporting high test-retest and inter-
observer reliability of QST in accordance with the DFNS protocol and training (Geber 
et al., 2011). QST has been suspected to be unreliable due to its subjective rating 
character (Yarnitsky and Granot, 2006), but it has been shown that subjective pain 
ratings correlate with neural activity in cortical regions associated with pain 
processing (Coghill and Eisenach, 2003). Furthermore, seemingly objective 
measures like corneal confocal microscopy or gold standards like skin biopsy for 
determining the intraepidermal nerve fiber density for detecting small fiber 
neuropathy have been conflictingly reported to be of high (Smith et al., 2005; Pacaud 
et al., 2015) or rather moderate (Wopking et al., 2009; Hertz et al., 2011) reliability, 
indicating that standardized procedures and extensive quality control are of higher 
importance for reliability than the method itself.  
These results hold direct implications on the future planning for multi-center studies 
and clinical trials. To our knowledge, these have been avoided since the 
homogeneity of QST results across different labs has been previously doubted. 
However, it seems to be possible to produce highly reliable DFNS QST results 
across different research units, and, more importantly, also across countries and 
languages. The DFNS protocol is applied by trained examiners meanwhile in more 
than 70 research units in 21 countries across the world, and it is a future challenge to 
show that QST data from other continents beyond Europe is comparable to the 
reference data. A first indication is a study by Haroun et al. (unpublished to this 
point), in which a well-trained examiner performed DFNS QST in 52 healthy 
participants in Mumbai, India, without systematic deviations from the DFNS reference 
data.  
There are no center effects that can be assigned to systematic heterogeneity in a 
meaningful way, and the I² Index for heterogeneity between centers was found to be 
above 0% only for the mechanical detection threshold (5.4%) and pressure pain 
threshold (41.8%) in healthy participants. While 5% for MDT can safely be assigned 
to normal scatter in (comparably) small samples, 42% for PPT can be considered as 
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high. This value was mainly influenced by two centers from Denmark and Sweden, 
but due to the broad confidence intervals of the center-specific means, the 
confidence interval of I² is still 0% to 66%, and Higgins and Thompson state that an I² 
Index with a confidence interval that includes 0% can be considered as no systematic 
heterogeneity (Higgins and Thompson, 2002). An indication of true heterogeneity in 
the assessment between the centers would be if the deviation from the overall mean 
in PPT of the above mentioned two centers was found also in the polyneuropathy 
and peripheral nerve injury group. This is only the case for one center in the 
polyneuropathy group, while the other three center-specific means (one center in the 
PNP group and both centers in the PNI group) lie very closely to the overall mean of 
PPT in the patient groups.  Nonetheless, the high heterogeneity in PPT may be 
explained by the methodological peculiarities of the PPT assessment. This 
parameter, which assesses the only deep pain threshold in the protocol, is harder to 
be performed in the standardized way as per protocol in comparison to the other QST 
parameters, especially regarding the speed of the stimulus application, as it is the 
only stimulus ramp in the DFNS protocol that is controlled manually (Rolke et al., 
2005; Mainka et al., 2014). Therefore, it is plausible that we found heterogeneity only 
in this parameter. The effect might be reduced if a device with a defined stimulus 
ramp application would be used (Mainka et al., 2014), still, this would further increase 
costs of the DFNS protocol. The effects are smaller over muscle than over bone 
structure (Mainka et al., 2014), therefore, the PPT is tested over muscle. 
One of the main drawbacks of the analysis is the small group sizes per center. While 
in healthy participants a normal range is well defined for DFNS QST (Rolke et al., 
2006a; Magerl et al., 2010; Pfau et al., 2014), however, patients suffering from 
painful neuropathies present with broadly scattering QST profiles (Maier et al., 2010; 
Backonja et al., 2013). It is important to keep in mind that the fact that CIs and I² 
indices are not higher for patients in comparison to healthy participants does not 
imply that heterogeneity between patients is comparable to heterogeneity between 
healthy participants. Both I² and the forest plot indicate measures of heterogeneity 
between centers, not between subjects. Individual differences can be influenced by 
many factors, such as underlying disease and its duration (Maier et al., 2010; 
Krumova et al., 2012a; Backonja et al., 2013). A high degree of individual scatter can 
lead to broad confidence intervals of the center-specific means, which may lead to 
underestimating the true heterogeneity (false negative results).  On the other hand, 
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this may lead to a high degree of heterogeneity that is in fact not due to differing 
application of the QST protocol but different patient groups in phenotype of pathology 
or disease duration (false positive results).  
While we can rule out the latter in our case, as we found no heterogeneity in the 
patient groups, the former is more difficult to conclude on. In 50% (11 of 22) of the 
QST parameters in the patient groups, the upper boundary of the 95% confidence 
interval of the I² Index is above 60%, indicating that although all I² values are found to 
be 0%, we find a very different picture if we look at the upper boundaries of the 
confidence intervals. Center-specific mean z-values scatter broadly for many QST 
parameters in the patient groups (e.g. mechanical pain threshold), and the I² values 
are low only because of the broad confidence intervals of the center-specific means. 
This emphasizes that our results should be treated with some caution, and analyses 
in larger patient groups may produce more nuanced results. Broad individual scatter 
within and between the centers in combination with small sample sizes can also 
result in the model finding no center-specific mean (Self and Liang, 1987; Andrews, 
1997), as it has been the case for wind-up ratio and vibration detection threshold in 
patients suffering from peripheral nerve injury. This should not be interpreted as a 
definitive lack of heterogeneity between the centers, but merely reflect that on the 
basis of the underlying data we cannot make any clear statements about 
heterogeneity for these parameters in the PNI group. 
4.2 Sensory phenotypes in patients 
[The following section has been taken in parts and modified from (Baron et al., 2017) 
and (Vollert et al., 2017a).] 
In a cluster analysis of n = 902 patients suffering from peripheral neuropathic pain 
without a predefined number of clusters, we found that a three-cluster-solution best 
describes patients with peripheral neuropathic pain. All subgroups occurred in 
relevant numbers across etiologies, but frequencies differed between the entities. 
This 3-cluster solution and the structure of the sensory profiles could be reproduced 
in the validation cohort. It matches the three subgroups described in smaller studies 
in patients with PHN almost 20 years ago (Fields et al., 1998). The subsequently 
developed algorithm enables individual allocation of patients to one or more sensory 
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phenotypes, and, further, can separate patients from healthy participants with a very 
high specificity of 94% and a sensitivity of 78%. 
Although the presented algorithm offers a barrier for excluding healthy participants, 
this should be considered within the clinical context. We decided on a rather 
conservative criterion with high specificity. It should be noted that patients eligible for 
clinical trials are usually screened beforehand, have been shown to have a lesion or 
disease and have spontaneous pain. Confirming neuropathic pain is relying on a 
grading system, following four steps:  
1. a history of a relevant neurological lesion or disease,  
2. anatomically plausible pain distribution  
3. sensory signs of neuropathy, and finally  
4. diagnostic tests confirming the lesion or disease (Finnerup et al., 2016).  
Our algorithm serves as step (3) for confirming or dismissing neuropathic pain, but on 
an averaged level across a full profile: e.g., a strongly decreased vibration or thermal 
detection in an otherwise normal profile would be considered a single negative 
sensory sign, but might still result in a high averaged probability of being healthy in 
this algorithm. Further studies will provide insights, if single negative sensory signs or 
a phenotype probability is more meaningful. A second use of our algorithm is for 
stratification of patients suffering from neuropathic pain according to pain phenotype, 
and its efficacy will have to be validated in future RCTs. 
4.2.1 Sensory loss phenotype 
Cluster 1 (42%) was characterized by a loss of small and large fiber function and the 
presence of paradoxical heat sensations. These patients did not suffer from sensory 
gain except a mild dynamic mechanical allodynia in few patients. Roughly 52% of 
patients with polyneuropathy fell into this category indicating dying-back 
degeneration of nearly all fiber classes. Interestingly, 43% of patients with painful 
radiculopathy demonstrated this sensory pattern, suggesting severe degeneration of 
sensory fibers within the affected nerve root. Paradoxical heat sensation was most 
frequent, underpinning the notion that it is induced by a loss of afferent input although 
at face value it is a positive sensory sign possibly related to a central disinhibition 
process (Yarnitsky and Ochoa, 1990; Hansen et al., 1996). 
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The sensory profile is similar to that of a compression nerve block (Fruhstorfer, 1984; 
Yarnitsky and Ochoa, 1991; Baumgartner et al., 2002). It likely represents the 
"deafferentation" or "painful hypoesthesia" subgroups described by others (Fields et 
al., 1998; Baumgartner et al., 2002; Truini et al., 2009; Hatem et al., 2010). The 
spontaneous pain was likely due to ectopic action potentials generated in proximal 
sites of injured nociceptors (Campbell and Meyer, 2006) e.g., in the dorsal root 
ganglion or in deafferented central nociceptive neurons (Devor et al., 1992; Orstavik 
et al., 2006; Serra et al., 2012). 
4.2.2 Thermal hyperalgesia phenotype 
Cluster 2 was characterized by relatively preserved large and small fiber sensory 
function in combination with heat and cold hyperalgesia and only low intensity 
dynamic mechanical allodynia. Burning pain quality in this cluster was less prominent 
than in the other groups, consistent with findings in Guillain-Barré syndrome where 
burning pain was associated with small fiber deficits (Martinez et al., 2010). This 
pattern occurred in 33% of all peripheral neuropathic pain patients regardless of 
etiology. The fact that in one third of all patients the cutaneous sensory function was 
relatively preserved despite documented nerve damage indicates that peripheral 
neuropathic pain may be associated with effective cutaneous regeneration and 
sensitized nociceptors. 
The sensory profile is similar to that of a UVB burn lesion (Gustorff et al., 2013) and 
is likely due to peripheral sensitization (Treede et al., 1992). It represents the 
"irritable nociceptor" subgroup described by others (Fields et al., 1998; Ochoa et al., 
2005; Demant et al., 2014; Demant et al., 2015). Sensitized nociceptors are 
associated with overexpression of channels and receptors leading to pathological 
spontaneous discharges and a lowered activation threshold for thermal (heat and 
cold) and mechanical stimuli. Ongoing hyperactivity in surviving nociceptors may be 
responsible for ongoing pain (Campbell and Meyer, 2006) and may lead to some 
central sensitization in the spinal cord dorsal horn, so that tactile stimuli conveyed in 
A-fibers become capable of activating central nociceptive neurons. As a result, 
mechanical stimuli induce enhanced pain percepts, i.e., pinprick hyperalgesia and 
dynamic mechanical allodynia (von Hehn et al., 2012). Since these types of 
mechanical hyperalgesia were only present in about 20% of the patients, peripheral 
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nociceptor drive obviously does not always induce central sensitization (Truini et al., 
2013). 
4.2.3 Mechanical hyperalgesia phenotype 
Cluster 3 (24%) was characterized by a predominant loss of cold- and heat-sensitive 
small fiber function in combination with blunt pressure hyperalgesia, pinprick 
hyperalgesia and more frequent dynamic mechanical allodynia. The profile was most 
commonly present in patients with PHN (47%). It is similar to the one induced by 
high-frequency electrical stimulation of the skin that is capable of inducing spinal 
long-term potentiation (Randic et al., 1993; Lang et al., 2007) and likely equivalent to 
"neurogenic hyperalgesia" or "central sensitization" subgroups described by others 
(Fields et al., 1998; Baumgartner et al., 2002). Central sensitization is prominent for 
mechanical stimuli (Baumann et al., 1991; Simone et al., 1991; Treede et al., 1992) 
but not thermal stimuli. The dissociation of thermal and mechanical hyperalgesia may 
be explained by differences in neural signaling of thermal and mechanical pain that 
starts with peripheral encoding in distinct subsets of nociceptors (Cavanaugh et al., 
2009; Henrich et al., 2015). Ongoing pain in this subgroup indicates spontaneous 
activity in the nociceptive system, which may originate in the peripheral and/or central 
nervous system. 
4.2.4 Sample size recommendations 
While a series of studies showed that a post-hoc responder analysis can reveal 
phenotypes that are important to predict treatment response (Attal et al., 2004; 
Wasner et al., 2005; Edwards et al., 2006; Simpson et al., 2010; Westermann et al., 
2012; Katz et al., 2015; Attal et al., 2016; Mainka et al., 2016; Reimer et al., 2017), 
the first phenotype-stratified, randomized, placebo-controlled trials have been 
published only recently (Demant et al., 2014; Demant et al., 2015). In these studies, 
oxcarbazepine showed a superior effect over placebo in a subgroup with “irritable 
nociceptors”, a group with a sensory profile very similar to the thermal hyperalgesia 
phenotype in this study. In contrast, for topical lidocaine no group difference could be 
demonstrated. 
The main problem with the definition of “irritable nociceptors” based on individually 
abnormal QST values and loss and gain of functions patterns (Rolke et al., 2006a; 
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Maier et al., 2010) is that it is based on a statistically very sound, but strictly 
conservative approach with (comparably) low sensitivity. For instance in diabetic 
polyneuropathy the “irritable nociceptor” phenotype is virtually not present 
(Themistocleous et al., 2016). 
The approach taken in this study does, in contrast, not rely on individually abnormal 
QST values, but focusses on cluster centroids. An appealing advantage of this 
dynamic method can be seen in Figure 9. The thermal hyperalgesia phenotype, 
which is similar to the “irritable nociceptor” and may have similar underlying 
mechanisms of pain generation, is found to be a prominent phenotype in a 
reasonable subgroup of roughly one third of the patients with neuropathic pain due to 
diabetic polyneuropathy. In a cohort of patients suffering from PHN, PNP or PNI 
treated with oxcarbazepine (Demant et al., 2014), the thermal hyperalgesia 
phenotype is similarly effective as predictor of treatment efficacy compared to 
phenotyping by the “irritable nociceptor” classification. 
To use stratification into subgroups in clinical trials a large patient population must be 
screened beforehand. As screening with QST may be considered expensive and 
time-consuming, not only needs the final stratified study population be considered, 
but also the number of patients necessary to screen. Thus, a solid sample size 
calculation is a prerequisite for a stratified study. In Table 9 we present sample size 
numbers for screening of populations for painful diabetic polyneuropathy, painful 
peripheral nerve injury and post-herpetic neuralgia in relation to estimated effect size 
(0.3 vs. 0.5 vs. 0.7) and study design (parallel vs. crossover). Crossover sample 
sizes are overall “realistic” numbers – across phenotypes and clinical etiology based 
entities. If a parallel study design is intended, however, phenotype stratification may 
only be possible if a high effect size (e.g. 0.7) is anticipated. Another way to deal with 
high numbers to screen would be to limit the screening process to few centers, while 
the study main RCT can be conducted after screening at multiple sites.  
Of the two methods of sorting patients to phenotypes presented in parallel here, we 
do not recommend one or the other in general, because they have individual 
advantages and disadvantages. The deterministic approach, sorting each patient to 
exactly one phenotype, ignores that multiple mechanisms of pathology may be 
present in a patient, and that these mechanisms may overlay each other and result in 
a sensory phenotype that cannot easily be allocated to one phenotype over the other. 
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The probabilistic approach, however, holds its own challenges: while the overlap 
between phenotypes is reasonable for peripheral nerve injury and post-herpetic 
neuralgia, patients with diabetic polyneuropathy tend to present more than one 
phenotype with significant probability. This effect, probably caused by the 
overwhelming effect of loss symptoms in these patients, may dilute especially the 
mechanical hyperalgesia phenotype, and to a lesser extend the thermal hyperalgesia 
phenotype. When screening for these phenotypes in patients with diabetic 
polyneuropathy, this limitation should be considered by rather using the deterministic 
algorithm (or a probabilistic assignment on mechanistic basis developed in 
participants under surrogate models). For peripheral nerve injury and post-herpetic 
neuralgia, a notable part of the patients (21% and 30%, respectively) is not sorted to 
any phenotype in the probabilistic algorithm and therefore excluded from the 
analysis. While this is acceptable for phenotype-stratified trials, it becomes a problem 
if the algorithm would be used for designing individual patients’ treatment strategy in 
the future. Again, the deterministic approach might be favorable in this case.  
4.3 Subgrouping human surrogate models 
[The following section has been taken in parts and modified from (Vollert et al., 
2017b).] 
While the clustering approach for human surrogate models without a-priori 
assumptions did not lead to a sufficient result, a mechanistically guided grouping of 
models into surrogates for denervation, peripheral sensitization and central 
sensitization led to three mechanistic phenotypes that show high similarity to the 
phenotypes heuristically found in patients. 
4.3.1 Nerve blocks as human surrogate model of denervation 
The sensory profile of human surrogate models for denervation (i.e. compression 
block and topical lidocaine) was characterized by pronounced loss in thermal and 
mechanical detection thresholds in combination with paradoxical heat sensations. 
These patterns have been reported in previous single center studies (Ziegler, 1999; 
Klein et al., 2005; Krumova et al., 2012b) and may hence serve to validate our multi 
center QST profiling approach. Consistent with its selective effect on myelinated 
nerve fibers, compression nerve block had larger effects on mechanical and cold 
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detection thresholds than on warm detection threshold (Ziegler, 1999; Henrich et al., 
2015). Paradoxical perception of cooling stimuli as warm has been reported by some 
but not all of these studies (Fruhstorfer, 1984). Pinprick stimuli are often perceived as 
less painful in complete A-fiber block (Ziegler, 1999; Henrich et al., 2015), while mild 
pinprick hyperalgesia has been found associated with preserved A-delta fiber 
function (Andrew and Greenspan, 1999; Jørum et al., 2000) Topical lidocaine had 
mild effects when compared to complete conduction block by regional anesthesia 
(Gandevia and Phegan, 1999; Klein et al., 2005). Other clinical trials using this 
lidocaine patch did not assess sensory profiling.  
4.3.2 Primary hyperalgesia as human surrogate model of peripheral sensitization 
The profile of surrogate models of peripheral sensitization (topical capsaicin or UVB 
radiation) was characterized by pronounced hyperalgesia to heat, pressure and 
pinprick pain, but also presented very mild thermal sensory loss. Primary nociceptive 
afferents are easily sensitized to heat stimuli, but much less so to von Frey or 
pinprick stimuli (Treede et al., 1992). Peripheral sensitization to heat may be 
explained by phosphorylation of the heat-gated cation channel TRPV1 through 
multiple pathways (Voets et al., 2004), but has also been shown to be induced by 
TRPA1 agonist allyl-isothiocyanate (Andersen et al., 2017). While some peripheral 
sensitization to blunt pressure has been reported before (Kilo et al., 1994), pinprick 
hyperalgesia in these models may indicate additional central sensitization induced by 
enhanced peripheral nociceptive input to the spinal cord. Sensory loss occurred 
mostly in the topical capsaicin model and was restricted to thermal detection 
thresholds; this likely reflects desensitization by the TRPV1 agonist capsaicin, which 
is the intended clinical mode of action (Hayman and Kam, 2008). 
4.3.3 Secondary hyperalgesia as human surrogate model of central sensitization 
Human surrogate models of central sensitization (intradermal capsaicin and electrical 
high-frequency stimulation) were characterized by pronounced pinprick hyperalgesia, 
but also pronounced thermal sensory loss. Other human surrogate models using 
intra-cutaneous electrical stimulation have not yet undergone full sensory profiling, 
but published data are also consistent with a secondary hyperalgesia model (Koppert 
et al., 2001). Combined studies in monkey and humans using i.d. capsaicin have 
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shown pronounced increases in both WDT and high threshold spinal neuron output 
despite unchanged A- and C-nociceptor input (Baumann et al., 1991; Simone et al., 
1991). The same studies suggested that dynamic mechanical allodynia is a hallmark 
sign of central sensitization. Hyperalgesia to blunt pressure was mild in these models 
as compared to the primary hyperalgesia models, suggesting that this type of 
mechanical hyperalgesia may be primarily peripherally mediated (Ochoa, 1993; 
Koltzenburg et al., 1994). Tactile sensory loss has been reported in human surrogate 
models of secondary hyperalgesia (Magerl and Treede, 2004) and also in patients 
with pinprick hyperalgesia (Geber et al., 2013). An inverse spinal gate with small fiber 
input inhibiting processing of large fiber input (Zimmermann, 1968; Mendell, 2014) 
has been suggested as a mechanism. Thermal sensory loss is a new finding, 
suggesting that broad loss of detection of non-painful stimuli may be a characteristic 
feature of central sensitization (according to the IASP definition, this includes 
contributions by descending control systems). This implies that sensory loss in 
chronic pain patients does not necessarily have to be due to structural changes (e.g. 
intraepidermal nerve fiber loss), but may also be a functional sign, and hence 
potentially sensitive to analgesic treatment regimes.  
Additionally, the secondary hyperalgesia phenotype would have been suspected in 
the skin surrounding a primary hyperalgesia area induced by topical capsaicin or 
UVB irradiation. Sensory profiles (Fig. 11 and Table 10) confirmed this prediction, 
albeit in mild form. This may explain why the sorting algorithm assigned only 63% 
(skin surrounding topical capsaicin) and 4% (surrounding UVB) to the secondary 
hyperalgesia phenotype.  
4.3.4 Other human surrogate models 
The sensory profile of topical lidocaine plus topical capsaicin displays a combination 
profile of nerve block and primary hyperalgesia, but is unlike the secondary 
hyperalgesia phenotype. In the cluster analysis of neuropathic pain patients (Baron et 
al., 2017), the heuristic “mechanical hyperalgesia” phenotype exhibited a 
combination of sensory loss and hyperalgesia; one might have expected that this 
mixture could be induced by combining an experimental nerve block with an 
experimental hyperalgesia model. The present analysis indicates that primary and 
secondary hyperalgesia models are still distinguishable in the presence of a 
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concomitant mild nerve block. This finding suggests that sensory profiling may also 
be able to distinguish between contributions of peripheral vs. central sensitization in 
patients with neuropathic pain that have concomitant sensory loss.  
4.3.5 Mechanistic significance of heuristically found phenotypes  
QST data for both patients and human surrogate models were normalized to the 
same published reference data. Therefore, we could immediately apply the sorting 
according to surrogate model profiles to our previously published patient data. 
Sorting of 902 neuropathic pain patients into mechanistic phenotypes led to a similar 
distribution as the original heuristic clustering (65%, Cohen's κ=0.44, note that the 
expected value of random sorting is 33%). This supports previous mechanistic 
interpretations of the clinically found phenotypes: the thermal hyperalgesia patient 
phenotype shows strong overlap with surrogate models of primary hyperalgesia. Both 
show no pronounced loss of thermal detection, which indicates intact small fiber 
function in both patients and models. This supports previous interpretations as 
irritable nociceptor (Fields et al., 1998) and peripheral sensitization (Truini et al., 
2013). Both evoked and ongoing pain is likely to be due to surviving nociceptors in 
these patients.  
The mechanical hyperalgesia patient phenotype shows a strong overlap with 
surrogate models of secondary hyperalgesia, which supports an interpretation of this 
phenotype to be a phenotype of reorganization or central sensitization. Substantial 
thermal sensory loss (indicating loss of small fibers or small fiber function) suggests 
that also damaged nociceptors are involved, generating ongoing pain and inducing 
central sensitization (Baron et al., 2013).  
The sensory loss patient phenotype shows a strong overlap with experimental nerve 
blocks. These blocks were frequently used as tools to identify normal sensory 
function of fiber classes (A vs. C), but not yet widely recognized as mimicking 
aspects of neuropathic pain (Baumgartner et al., 2002; Klein et al., 2005). Both the 
clinical phenotype and the surrogate models are dominated by loss of small and large 
fibers or fiber function. This supports an interpretation as denervation or 
deafferentation, where central neurons may develop denervation super-sensitivity to 
other inputs (Colloca et al., 2017). Mild pinprick hyperalgesia appears to be intrinsic 
to these mechanisms.  
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While this relationship of patient phenotype and mechanistically defined surrogate 
model phenotype was true for about 2/3 of the patients, most of the remaining third 
were assigned to the nerve block phenotype according to the surrogate models vs. 
one of the hyperalgesia phenotypes in the heuristic patient cluster analysis. This 
systematic shift is consistent with the presence of partial nerve damage in most of the 
neuropathic pain conditions that may lead to coexistence of denervation and 
sensitization of the remaining pathways (Campbell and Meyer, 2006). In fact, in the 
probabilistic sorting algorithm, roughly one third of the patients had evidence for 
multiple mechanisms, most frequently a combination with the denervation phenotype. 
Of interest, the primary hyperalgesia phenotype was more frequent than the 
secondary hyperalgesia phenotype, suggesting that the relevance of peripheral 
sensitization of surviving nociceptors may have been underestimated in the past. In 
turn, central sensitization may be more frequent than the secondary hyperalgesia 
phenotype, since it may also be induced by ectopically generated impulses from 
damaged nociceptors or by enhanced input from sensitized nociceptors. Based on 
these findings, the probabilistic sorting may be a useful approach for mechanism-
based patient stratification. These data cover, however, only peripheral neuropathic 
pain, and to this point we cannot make any extrapolations onto, e.g., central pain, 
nociceptive pain, or deep pains. 
4.4 Limitations 
[The following section has been taken in parts and modified from (Vollert et al., 
2016a), (Baron et al., 2017), (Vollert et al., 2017a) and (Vollert et al., 2017b).] 
This analysis is based on QST z-values, which are dependent on the availability and 
quality of the underlying normative data, which are constantly in development (Rolke 
et al., 2006a; Blankenburg et al., 2010; Magerl et al., 2010; Pfau et al., 2014). There 
are methodological limits in the assessment, e.g., for the cold pain threshold at the 
feet, there is only a small window for abnormal values narrowing with growing age 
(Rolke et al., 2006a) (compare abnormal findings for CPT in patients with 
polyneuropathy), some sharp mechanical stimuli that are part of the standard 
protocol are too painful if applied in sensitive body areas as the cheek (Rolke et al., 
2006a) or in children (Blankenburg et al., 2010). This is especially a problem in 
assessing the wind-up ratio, as for an important part of the patients, either the 
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sharpest stimulus (512nm) is rated as not painful (and a ratio of zero cannot be 
calculated), or the softest stimulus is rated as too painful to endure a series of ten 
stimuli. This leads to a missing rate of WUR of over 10% of the patients (Baron et al., 
2017).    
Since the inclusion criteria slightly differed between the three consortia, there is no 
perfect homogeneity of patients’ clinical history within etiologies. Furthermore, in 
contrast to short-term stability of QST long-term stability over weeks has not been 
studied largely and is known to change over time during major events like 
adolescence (Hirschfeld et al., 2012). Hence, it is unknown whether patients can shift 
from one cluster into another. Patients may, however, suffer from more than one type 
of mechanism which changes during the course of chronicity.  
The sample size calculations in Table 9 show both advantage and disadvantage of a 
QST-based phenotype stratification for clinical trials. A novel drug that is aiming at a 
phenotype that is only present in a fifth of the population will never show an effect 
superior to placebo in a non-stratified population. On the other hand, many patients 
must be screened to identify an eligible subpopulation, and screening with QST 
needs substantial training to be reliable. Furthermore, some QST parameters are 
mechanistically linked and therefore probably intercorrelated (e.g., CDT or WDT and 
TSL). In the presented algorithm, these domains will be slightly overweighed. While 
beyond the scope of this thesis, a factorial analysis of the QST protocol is one of the 
upcoming tasks to show the importance and meaning of each parameter in relation to 
the full protocol. 
The human surrogate models entered into our analysis do not explicitly cover the 
actions of endogenous pain modulating systems (Kennedy et al., 2016), which may 
also play an important clinical role in pain generation. Descending modulation may 
contribute to the secondary hyperalgesia phenotype, but might also exhibit yet 
another sensory profile. This implies that the list of distinguishable sensory 
phenotypes may be longer than the three we describe, but not shorter.  
In many cases, surrogate models were tested in proximal upper or lower limbs, for 
which no separate published reference data are available (Rolke et al., 2006a; 
Magerl et al., 2010; Pfau et al., 2014). This may have confounded our z-values. To 
control for this factor, we compared effect sizes of treatment vs. untreated sites 
(same area before treatment or contralateral, untreated side) to effects on z-values. 
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These data showed that effect sizes and z-values generally concur, and that the 
confounding element of non-reference areas is neglectable. One exception should be 
noted: secondary hyperalgesia models (i.d. capsaicin and cutaneous HFS) show 
significant loss of thermal detection on the z-scale, while effect sizes compared to the 
untreated area are present, but smaller (0.2 – 0.7). Loss of thermal detection might 
therefore be overestimated in the secondary hyperalgesia mechanism. Still, it should 
be noted that patients are often tested beyond reference areas as well, so this 
limitation partly reflects a normal clinical setting.   
An additional limitation for the use in large clinical trials is that the QST protocol 
requires substantial training and an expensive device. In the long run, both for large 
trials and daily clinical practice, an approximation via a simple bed-side testing 
protocol would be highly valuable. 
4.5 Impact and conclusions 
[The following section has been taken in parts and modified from (Vollert et al., 
2016a), (Baron et al., 2017), (Vollert et al., 2017a) and (Vollert et al., 2017b).] 
In summary, this work showed that  
1. centers across Europe can produce similar results when assessing patients’ 
and participants’ sensory profile,  
2. profiles of patients suffering from peripheral neuropathic pain persistently 
show three sensory subgroups, which are present across etiologies, genders 
and age decades, 
3. a simple algorithm can be used for stratification of patients into these three 
sensory phenotypes for use in clinical trials and in the future to indicate 
individual patients’ optimal treatment strategies, 
4. frequencies of these phenotypes differ between etiologies of neuropathic pain, 
which should affect the number of patients screened for clinical trials, 
5. similar phenotypes are identified based on mechanistic assumptions in human 
surrogate models of neuropathic pain. 
The parts of this work that are already published were well accepted in the pain 
research community (Dworkin and Edwards, 2017). As a result of this analysis, the 
European Medicines Agency’s (EMA) committee for medicinal products for human 
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use recommends the phenotype stratification presented here for determining eligible 
sensory phenotypes of patients in exploratory trials on neuropathic pain, as also 
incorporated in the new EMA guideline for clinical development of new treatments for 
pain (European Medicines Agency, 2016). Using the probabilistic sorting according to 
human surrogate model profiles, patients suffering from neuropathic pain can be 
tentatively stratified in future studies to presumed underlying mechanisms. It should 
be noted, however, that the three classes of human surrogate models studied here 
likely represent combined rather than single mechanisms (e.g. peripheral and central 
sensitization in primary hyperalgesia). This, however, is likely true also for studies in 
awake behaving animals. Therefore, a reverse translation approach may be useful 
for developing novel analgesic medications, if they are initially validated in animal 
models of nerve block, primary or secondary hyperalgesia. Medications effective on 
these phenotypes can easily be validated in human surrogate models and then 
transferred to subgroups of neuropathic pain patients. 
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5 SUMMARY 
Quantitative Sensory Testing (QST) following the DFNS (German Research Network 
on Neuropathic Pain) protocol assesses the function of the somatosensory nervous 
system. Long-term aim of QST research is the establishment of a mechanism-based 
classification of neuropathic pain. Over the last years, a central database with QST 
assessments of healthy participants, healthy participants under human surrogate 
models of neuropathic pain, and patients suffering from neuropathic pain has been 
built within the European consortia IMI Europain, Neuropain and the DFNS.  
Aim of this work was to show that QST assessment is comparable between the 
participating centers across Europe in an analysis of heterogeneity, to use 
unsupervised clustering methods to identify subgroups of sensory profiles appearing 
across etiologies of peripheral neuropathic pain and may indicate underlying 
mechanisms of pathophysiology, to develop an individual assignment algorithm 
sorting QST profiles to these subgroups, to estimate the frequency of these 
subgroups across the common entities of peripheral neuropathic pain diabetic 
polyneuropathy, peripheral nerve injury and post-herpetic neuralgia and to further 
validate the subgroups identified in patients in surrogate models of neuropathic pain, 
in which the underlying mechanisms are well described. 
Heterogeneity was overall low between the 11 participating European centers and 
the 13 QST parameters for healthy participants, and virtually non-existing for patients 
suffering from polyneuropathy or peripheral nerve injury. The cluster analysis found 
three sensory phenotypes, which are mainly characterized by either sensory loss 
(SL), intact sensory function and mild thermal hyperalgesia (TH) or loss of thermal 
detection and mild mechanical hyperalgesia (MH). The most common phenotype in 
diabetic polyneuropathy was SL (83%), followed by MH (75%) and TH (34%, note 
that percentages are overlapping and not additive). In peripheral nerve injury, 
frequencies were 37%, 59% and 50%, and in post-herpetic neuralgia, 31%, 63% and 
46%. Surrogate models of nerve block were similar to the SL phenotype, but also 
showed mild pinprick hyperalgesia and paradoxical heat sensations. Peripheral 
sensitization models resembled the TH phenotype, while models of central 
sensitization showed high similarities to the MH phenotype. 
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These data suggest that classifying patients based on QST profiles in an approach 
developed hypothesis-free in patients and validated in models with well-described 
mechanisms may be a good strategy for mechanism-based stratification of 
neuropathic pain patients for future clinical trials, as encouraged by the European 
Medicines Agency EMA. 
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